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ABSTRACT
PROTECTIVE EFFECTS OF PIGMENTATION IN PSEUDOMONAS AERUGINOSA:
INSIGHTS ON PYOMELANIN PRODUCTION AND INHIBITION BY NTBC
by
Laura M. Ketelboeter
The University of Wisconsin-Milwaukee, 2016
Under the Supervision of Professor Sonia L. Bardy

Pyomelanin is an extracellular, reddish-brown pigment produced by several
environmental and pathogenic bacteria and fungi. It is derived from the
phenylalanine/tyrosine catabolism pathway and is produced when homogentisate
(HGA) is secreted from the cell, auto-oxidized, and self-polymerized. Point mutations or
chromosomal deletions in hmgA, which encodes homogentisate 1,2-dioxygenase, result
in the accumulation of HGA and subsequent pyomelanin production. My work showed
that the pyomelanogenic Pseudomonas aeruginosa clinical isolate PA1111 had a
chromosomal deletion of hmgA, while a second pyomelanogenic clinical isolate,
DKN343, had a loss of function mutation in HmgA. The 4-hydroxyphenylpyruvate
dioxygenase (Hpd) inhibiting compound 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3cyclohexanedione (NTBC) has been proposed as a treatment for microbial infections by
pyomelanin producers. NTBC inhibits Hpd by binding irreversibly to the ferrous metal
center in the active site of the enzyme, which should prevent HGA formation and
subsequent pyomelanin production. NTBC reduced pyomelanin production in a dose
dependent manner in both PA1111 and DKN343; DKN343, however, was more
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resistant to NTBC than PA1111. NTBC resistance studies revealed that the multi-drug
efflux pump MexAB-OprM was responsible for the inherent resistance to NTBC
observed in DKN343. One of the functions of pyomelanin is resistance to oxidative
stress, and treatment of PA1111 with NTBC resulted in increased sensitivity to H2O2
compared to the untreated strain. Additionally, reduction in pyomelanin production with
NTBC had no effect on PA1111 aminoglycoside minimum inhibitory concentrations,
which demonstrated that NTBC could possibly be used in conjunction with antibiotics.
Pyomelanin was involved in persistence of P. aeruginosa in mouse models of infection,
so I investigated macrophage-based killing of pyomelanogenic P. aeruginosa. My
results showed little difference in bacterial survival during RAW 264.7 infection between
pyomelanin producers and non-producers under different test conditions. My work
provided some data for the potential development of NTBC as a treatment for
pyomelanogenic microbial infections. NTBC shows some promise as a therapeutic
agent, but its effectiveness may be limited in organisms with high levels of antimicrobial
resistance such as P. aeruginosa. Future studies should focus on the prevalence of
NTBC resistance in other pyomelanogenic organisms to determine the future
applications of NTBC as an anti-microbial therapy.
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Chapter One

Overview of pyomelanin production and anti-virulence treatment in
Pseudomonas aeruginosa

1

1.1

Pseudomonas aeruginosa
Pseudomonas aeruginosa is a Gram negative bacterium in the Gamma

Proteobacteria class. It is rod shaped and has a single polar flagellum for swimming
motility. P. aeruginosa is found in diverse ecological environments including soil,
organic matter, water, plants, animals, and moist surfaces, and has the ability to form
biofilms (1). Additionally, P. aeruginosa is an opportunistic pathogen and is a common
cause of both acute and chronic infections in individuals who are compromised. P.
aeruginosa frequently colonizes the lungs of cystic fibrosis (CF) patients and forms
biofilms that are very difficult to eradicate, leading to persistent bacterial infections (2).
In addition, P. aeruginosa is frequently isolated from burn patients (3, 4), where it
causes an acute infection. P. aeruginosa has been implicated in a variety of other
infections, including pneumonia and upper respiratory tract infections, urinary tract
infections, eye infections such as keratitis, and infections in various other parts of the
body (1).
The persistence of P. aeruginosa infections is due, in part, to different
mechanisms of resistance to antimicrobial agents. Low outer membrane permeability
can prevent antimicrobial agents from entering the cell (5). Chromosomally encoded βlactamases can also inactivate β-lactam antibiotics (1). Biofilm formation results in
increased resistance to various antimicrobial agents (1, 6). This is likely due to the fact
that cells in a biofilm display heterogeneous physiology depending on where they are
located (7), and slow growing or dormant cells in a biofilm may be a resistant population
because many antimicrobial agents are dependent on actively metabolizing cells to be
effective (8). Additionally, multidrug efflux pumps have broad specificity for antibiotics
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and other antimicrobial agents and function in transporting these compounds from the
cell (9). These different resistance mechanisms make it difficult to treat P. aeruginosa
infections.
P. aeruginosa has 12 different resistance nodulation division (RND) efflux
pumps, four of which are known to contribute to antibiotic resistance (MexAB-OprM,
MexCD-OprJ, MexEF-OprN, and MexXY-OprM) (1). MexAB-OprM is constitutively
expressed in P. aeruginosa, and hyperexpression of mexAB-oprM has been observed
in multi-drug resistant clinical isolates (6). This hyperexpression is frequently due to
mutations in mexR, which encodes the MexR repressor for the mexAB-oprM operon
(10). Two other regulators of mexAB-oprM transcription have been identified. Mutations
in nalD can lead to hyperexpression of MexAB-OprM and multi-drug resistance in both
laboratory and clinical isolates of P. aeruginosa (11). NalD has also been shown to bind
to a second mexAB-oprM promoter, and a nalD mutant showed increased expression
from that promoter (12). Novobiocin can bind to NalD, causing it to dissociate from the
mexAB-oprM promoter, and result in increased mexAB-oprM expression (13)
Additionally, nalC mutants showed hyperexpression of mexAB-oprM (14). NalC
represses expression of armR, which encodes the anti-MexR repressor that binds to
MexR and prevents MexR from binding to the mexAB-oprM promoter, thereby resulting
in hyperexpression of mexAB-oprM (15). Pentachlorophenol induces expression of
armR via modulation of NalC repressor activity (15). Additionally, oxidative stress can
increase expression of mexAB-oprM (16). Since MexAB-OprM is constitutively
expressed, it contributes to intrinsic resistance to antimicrobial agents. It is able to
extrude several classes of antibiotics, as well as dyes, detergents, organic solvents,
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fatty acid synthesis inhibitors, and homoserine lactone (13), which demonstrates that it
has broad substrate specificity.
Other multi-drug efflux pumps can contribute to antibiotic resistance. MexXY is
induced in response to aminoglycoside, tetracycline, and macrolide antibiotics, as well
as oxidative stress (16, 17). Additionally, clinical isolates can express both MexABOprM and MexXY multi-drug efflux pumps (17). Nitrosative stress and chloramphenicol
are capable of inducing expression of mexEF-oprN (16). Induction of mexCD-oprJ
expression occurs in response to membrane damaging agents including biocides, dyes,
detergents, organic solvents, and cationic antimicrobial peptides such as polymyxin B
and colistin (16). MexCD-OprJ and MexEF-OprN are not usually expressed in wild type
P. aeruginosa under normal laboratory conditions, but are expressed in nfxB and nfxC
mutants, respectively (18). The fact that multi-drug efflux pump expression can be
induced by different stressors indicates that these pumps may not have evolved to
extrude antimicrobial agents and they likely play a role in stress response.
P. aeruginosa has a large genome, with several variable sections containing
genes that are involved in producing a variety of virulence factors, including secreted
proteins, toxins, and pigments (19). The four different pigments that can be produced by
P. aeruginosa are pyocyanin, pyoverdine, pyorubrin, and pyomelanin. Pyocyanin is a
blue-green pigment and is produced in 90-95 percent of P. aeruginosa isolates (20).
This pigment is a phenazine and redox active secondary metabolite that functions as a
virulence factor (20). Pyoverdine is a yellow-green pigment that functions as a
siderophore for iron acquisition (21). This pigment is widely distributed in Pseudomonas
species and over 60 pyoverdines have been identified to date (22). Pyorubrin is a red
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pigment that is rarely isolated and infrequently studied in P. aeruginosa (23, 24).
Pyomelanin is a reddish-brown pigment produced in some strains of P. aeruginosa (25).
This pigment is one of four types of melanin and will be described in detail in this work.

1.2

Types of melanin
Melanin production has been identified in many organisms, including animals,

bacteria, and fungi. In general, melanin pigments are composed of polymerized
phenolic or indolic compounds with an undefined structure that are dark in color (26,
27). These pigments are negatively charged and hydrophobic with a high molecular
weight (26, 27). Melanins are also susceptible to bleaching by oxidizing agents,
resistant to concentrated acid, and insoluble in aqueous or organic fluids (26, 27).
Melanin synthesis occurs through either phenoloxidases, such as tyrosinases, laccases,
and catacholases, or the polyketide synthase pathway (27). In bacteria, tyrosinases are
more common in melanin production than laccases (27). Melanin may provide a survival
advantage in the various environments encountered by bacteria and fungi and has been
associated with virulence of pathogenic organisms in hosts (26, 27).
Four types of melanin can be produced including eumelanin, pheomelanin,
dihydroxynaphthalene (DHN) melanin, and pyomelanin. Eumelanin is usually black or
brown and is formed from 3,4-dihydroxyphenyalanine (DOPA) by phenoloxidases (26,
28). This type of melanin can be found in bacteria, fungi, and animals (28-32).
Pheomelanin is red or yellow and is formed by the incorporation of cysteine with DOPA
(26, 28). Animals typically produce this type of melanin (28, 32). DHN-melanin is formed
from acetyl-CoA and malonyl-CoA via the polyketide synthase pathway and is usually
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black or brown (26, 33). This type of melanin is commonly found in fungi (31).
Pyomelanin is generally reddish-brown and is formed from homogentisate during
tyrosine catabolism (34). Both fungi and bacteria produce this type of melanin (27, 35).

1.3

Pyomelanin production
Pyomelanin has been reported in many clinical and environmental bacterial and

fungal species, including P. aeruginosa, Burkholderia cepacia complex, Vibrio cholerae,
Legionella pneumophila, Shewanella algae, Bacillus anthracis, Aeromonas media,
Acinetobacter baumannii, Sinorhizobium meliloti, Streptomyces coelicolor, Alteromonas
stellipolaris, Aspergillus fumigatus, Sporothrix sp., and Penicillium chrysogenum (25,
36-49). In these strains, pyomelanin is either naturally produced in the wild type strain or
is the result of mutation or deletion of genes involved in tyrosine catabolism. Natural
production of pyomelanin in bacterial and fungal species is important in allowing us to
study how the pigment is produced under different environmental conditions.
Inactivation of genes involved in pyomelanin production via mutation or deletion can
allow us to elucidate the functions of pyomelanin, as well as examine the individual
contributions of genes in tyrosine catabolism to pigment production.

1.3.1 Phenylalanine and tyrosine catabolism pathway
Pyomelanin is a negatively charged, extracellular, reddish-brown pigment derived
from the phenylalanine and tyrosine catabolism pathway (Figure 1.1) (34, 50). The
tyrosine catabolism pathway is conserved in almost all aerobic organisms and is used to
acquire energy from tyrosine breakdown (51). In this pathway, phenylalanine is first
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L-phenylalanine
PhhAB
L-tyrosine
PhhC
4-hydroxyphenylpyruvate
Hpd
homogentisate (HGA)
HmgA

HatABCDE
Secretion from cell,
auto-oxidation, and
self-polymerization

Pyomelanin

maleylacetoacetate
MaiA
fumarylacetoacetate
FahA
fumarate

acetoacetate
DhcAB
acetoacetyl-CoA
AtoB
acetyl-CoA

Figure 1.1. Phenylalanine/tyrosine catabolism pathway in P. aeruginosa. PhhA, phenylalanine-4hydroxylase; PhhB, pterin-4-α-carbinolamine dehydratase; PhhC, aromatic amino acid
aminotransferase; Hpd, 4-hydroxyphenylpyruvate dioxygenase; HmgA, homogentisate 1,2dioxygenase; MaiA, maleylacetoacetate isomerase; FahA, fumarylacetoacetase; DhcAB,
dehydrocarnitine CoA transferase, subunits A and B; AtoB, acetyl-CoA acetyltransferase; HatABCDE,
HatABCDE ABC transporter. P. aeruginosa nomenclature is used (Pseudomonas Genome Database
http://www.pseudomonas.com).
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converted to tyrosine by phenylalanine-4-hydroxylase (PhhA) and pterin-4-alphacarbinolamine dehydratase (PhhB). Tyrosine is then converted to 4hydroxyphenylpyruvate by an aromatic amino acid aminotransferase (PhhC or TyrB).
Next, 4-hydroxyphenylpyruvate is converted to homogentisate (HGA) by 4hydroxyphenylpyruvate dioxygenase (Hpd). After HGA is formed, it is converted to
maleylacetoacetate by homogentisate 1,2-dioxygenase (HmgA). Maleylacetoacetate is
converted to fumarylacetoacetate by maleylacetoacetate isomerase (MaiA or HmgC). In
the next step in the pathway, fumarylacetoacetate is split into fumarate and
acetoacetate by fumarylacetoacetase (FahA or HmgB). The last steps of the pathway
involve conversion of acetoacetate into acetoacetyl-CoA by the dehydrocarnitine CoA
transferase, subunits A and B (DhcA and DhcB), and finally the formation of acetyl-CoA
from acetoacetyl-CoA by the acetyl-CoA acetyltransferase (AtoB) (52). The end
products of tyrosine catabolism go into the TCA cycle (45, 53).
Pyomelanin production occurs when there is a defect in the tyrosine catabolism
pathway, either through mutations or deletions of key genes, or reduced enzyme activity
for the enzymes in the latter part of the pathway (HmgA, MaiA, and FahA) compared to
enzymes in the upper part of the pathway (54-56). In P. aeruginosa, it was found that
strains containing mutations in maiA and fahA did not produce pyomelanin, which
suggested that inactivation of hmgA was the only cause of pyomelanin production in
that organism (56). Several proteins in the phenylalanine and tyrosine catabolism
pathway have been implicated in pyomelanin production, and these proteins will be
discussed in detail below.
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1.3.2 Homogentisate 1,2-dioxygenase (HmgA)
One of the major proteins that impacts pyomelanin production is HmgA, which is
responsible for converting HGA to maleylacetoacetate. In P. aeruginosa, defects in the
hmgA gene, either through chromosomal deletions or point mutations, result in
pyomelanin production because the tyrosine catabolism pathway stalls and HGA
accumulates (55, 56). Pyomelanin is produced when HGA is secreted from the cell,
leading to auto-oxidation and self-polymerization (34, 56, 57). Secretion of HGA occurs
via the HatABCDE transport system, and defects in this transport system result in
reduced pyomelanin production (57).
Deletions of hmgA and potential defects in regulation of hmgA expression have
been identified in various strains of P. aeruginosa that produce pyomelanin. In the P.
aeruginosa pyomelanogenic clinical isolate PA1111, which was isolated from an acute
infection in a burn patient, a chromosomal deletion of hmgA was identified and
determined to be the cause of pyomelanin production in that strain (58, 59). Additional
studies of two clinical pyomelanogenic P. aeruginosa strains from CF patients showed
that one strain contained a deletion of hmgA, while the other strain had no mutations or
deletions of hmgA, which indicated that mutations in a transcriptional regulator may be
responsible for pigment production in that strain (56). Interestingly, downregulation of
hmgA in a chronic isolate of P. aeruginosa Australian epidemic strain-1 (AES-1) from a
CF lung did not result in pyomelanin production (60), which indicated that there was
enough functional HmgA produced to prevent pigment formation even when hmgA
expression was downregulated. These results demonstrate that chromosomal deletions
of hmgA may be a frequent cause for pyomelanin production in P. aeruginosa, and it
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can occur in isolates from both acute and chronic infections. Regulation of hmgA
expression may also be important in pigment production, as downregulation of hmgA
did not result in pigment production, while a strain with a possible defect in a
transcriptional regulator did show pyomelanin production.
Studies in several other bacteria have revealed defects in hmgA as a cause for
pyomelanin production. In some strains of V. cholerae, pyomelanin can be produced
under normal experimental growth conditions. Analysis of these strains revealed that
they contained either a 15 or 10 base pair (bp) deletion mutation in homogentisate
oxygenase, and the 15 bp deletion was conserved in six O139 strains that were studied
(61). Additionally, in a Burkholderia cenocepacia pyomelanogenic CF clinical isolate a
single point mutation in hmgA resulted in an amino acid change from a glycine to an
arginine at residue 378, and this mutation was conserved in three of four pigmented B.
cepacia complex strains (62). The G378R mutation in B. cenocepacia was located in
the iron cofactor binding region of HmgA, which could affect iron binding and
subsequent enzyme function (62). In A. media WS, it was recently reported that
pyomelanin is the major melanin produced in this strain, not L-DOPA melanin as
previously thought, and the hmgA gene was disrupted by an insertion of a different gene
in the opposite orientation (42). Conservation of deletions and mutations in hmgA is
important because it demonstrates stability of a defect across several strains of
bacteria, and could also represent a hot spot for mutations. Additionally, conservation of
mutations could represent horizontal gene transfer between different bacteria, which
would explain why they have the same mutation or deletion.
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Pyomelanin production has also been observed in several other bacterial and
fungal strains after transposon mutagenesis or in-frame deletion of hmgA, including B.
anthracis, Vibrio campbellii, S. meliloti, Pseudomonas chlororaphis, and A. fumigatus
(41, 44, 47, 63, 64). Creation of stable mutations in hmgA for bacteria that do not
produce pyomelanin in the wild type strain can allow us to study mechanisms of
pigment production in different bacteria, as well as allow us to study the functions of
pyomelanin in these bacteria.

1.3.3 4-hydroxyphenylpyruvate dioxygenase (Hpd)
The second major protein involved in pyomelanin production is Hpd, the enzyme
responsible for the production of HGA from 4-hydroxyphenylpyruvate. Transposon
mutagenesis or deletion of hpd led to an abolishment of pyomelanin production in B.
cenocepacia, L. pneumophila, P. aeruginosa, A. media WS, and A. fumigatus (39, 42,
47, 57, 62, 65). The lack of pigmentation in these hpd mutant strains demonstrates the
importance of Hpd in the production of the pyomelanin precursor molecule HGA. If Hpd
is not present, HGA cannot form, and pyomelanin production will not occur.
Additionally, expression of Hpd from the bacterial species A. stellipolaris LMG
21856, L. pneumophila, B. cenocepacia, and Streptomyces avermitilis, as well as the
archaeon Picrophilus torridus, in Escherichia coli resulted in pyomelanin production (36,
46, 66-68). E. coli does not possess genes for the tyrosine catabolism pathway;
therefore, expression of recombinant Hpd in E. coli produces HGA, which can oxidize
and polymerize to form pyomelanin. These results emphasize the importance of Hpd in
pyomelanin production and also show that Hpd from different microbial species are
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functional in E. coli. The ability to produce functional recombinant Hpd in E. coli can
allow researchers to further examine the functions and characteristics of this protein
independent of the organism from which it was originally isolated.

1.3.4 Other proteins implicated in pyomelanin production
Additional proteins involved in pyomelanin production include phenylalanine-4hydroxylase (PhhA) and pterin-4-alpha-carbinolamine dehydratase (PhhB), which
convert phenylalanine to tyrosine, and the aromatic amino acid aminotransferase
(PhhC/TyrB), which converts tyrosine to 4-hydroxyphenylpyruvate. phhA, phhB, and
phhC transposon mutants in a pyomelanogenic P. aeruginosa strain showed no
pigment production (57). In L. pneumophila, phhA mutants also showed reduced
pigmentation during growth (69). Additionally, phhA and tyrB mutants in A. media WS
showed reduced pigment production (42). These results show a functional role for
proteins in the upper part of the phenylalanine/tyrosine catabolism pathway in
pyomelanin production.
The conversion of phenylalanine to tyrosine by PhhAB is important in pyomelanin
production because in the absence of tyrosine in the environment, phenylalanine must
be converted to tyrosine for the phenylalanine/tyrosine catabolism pathway to eventually
produce the HGA needed for pigment production. The phhA mutants that showed
reduced pigmentation may have the ability to obtain tyrosine from the environment
when PhhA is non-functional, thereby allowing them to produce some HGA through
tyrosine catabolism. The phhA mutants that showed no pigmentation could exhibit
reduced uptake of tyrosine from the environment compared to the phhA mutants that
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did show some pigmentation, which would account for the differences in pyomelanin
production that were observed. It is also possible that the phhA mutants can obtain
tyrosine through aromatic amino acid biosynthesis, which could then allow them to
produce some pigment. Pseudomonas putida is capable of phenylalanine and tyrosine
biosynthesis from chorismate via chorismate mutase (PheA) and bifunctional
cyclohexadienyl dehydrogenase/3-phosphoshikimate 1-carboxyvinyltransferase
(PP1770/TyrA) (70). P. aeruginosa has a homolog for PheA (87.19 percent identity), but
3-phosphoshikimate 1-carboxyvinyltransferase prephenate dehydrogenase is a
pseudogene (71).
The conversion of tyrosine to 4-hydroxyphenylpyruvate by PhhC/TyrB is
important because 4-hydroxyphenylpyruvate is needed to produce HGA. The lack of
pigmentation in phhC mutants suggested that the bacteria do not possess additional
aromatic amino acid aminotransferases that can convert tyrosine into 4hydroxyphenylpyruvate. Reduced pigmentation in tyrB mutants, however, suggested
that there could be an additional enzyme functioning as an aromatic amino acid
aminotransferase that can contribute to the conversion of tyrosine to 4hydroxyphenylpyruvate, which would allow some HGA to be produced.
Other proteins may also be involved in pyomelanin production. In P. putida,
deletion of two genes encoding an acyl-CoA transferase involved in acetoacetate
degradation resulted in pigment production (53), which demonstrated that the proteins
encoded by those genes are important for a functional tyrosine catabolism pathway.
The homologous proteins for the P. putida acyl-CoA transferase in P. aeruginosa are
dehydrocarnitine CoA transferase, subunits A and B (DhcA, 85.78 percent identity;
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DhcB, 90.37 percent identity) (71). Although it has not been demonstrated that DhcA
and DhcB are involved in pyomelanin production in P. aeruginosa, it is certainly possible
that they could be involved since the homologous proteins in the closely related
organism P. putida have been implicated in pigmentation.

1.3.5 Laboratory growth conditions
Laboratory growth conditions may also affect pyomelanin production. Many
organisms require the addition of tyrosine to growth medium in order to produce
pyomelanin. In S. meliloti, addition of tyrosine to the medium enhanced pyomelanin
production (44). Additionally, in V. cholerae, pyomelanin was produced in low nutrient
conditions when tyrosine was supplemented, but never in rich media (54). Tyrosine
addition to media enhanced pigment production in L. pneumophila (66). In P.
chrysogenum, pyomelanin was produced when tyrosine was included in the growth
medium, and HGA was detected only in cultures grown with tyrosine (49). Pyomelanin
production in A. fumigatus occurred when strains were grown on media containing
tyrosine (47). Sporothrix complex species were also able to produce pyomelanin at
varying levels when they were grown in minimal media containing tyrosine (48). These
results demonstrate the importance of including tyrosine in growth medium. Additionally,
adding a specific concentration of tyrosine to a minimal growth medium can help
eliminate some of the variability in experimental results and show that pigment is
produced only under certain conditions. It is also possible that the concentration of
tyrosine in a rich medium is not high enough to induce pigment production in some
strains of bacteria and fungi.
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1.4

Regulation of pyomelanin production
In P. aeruginosa, the genes for phenylalanine/tyrosine catabolism are found in

several operons that are scattered in the genome (Figure 1.2). The phhABC genes are
found in an operon, and the transcriptional regulator phhR is divergently transcribed (50,
71). hpd is not in an operon, but it is located in close proximity to phhABC (71). The
hmgA-fahA-maiA genes are also found in an operon, and the probable transcriptional
regulator gene PA2010, which is homologous to the P. putida repressor hmgR that is
known to regulate the hmg operon, is divergently transcribed (50, 71). The dhcAB
genes form an operon, with atoB, which encodes the acetyl-CoA acetyltransferase,
directly downstream but not part of the operon, and the transcriptional regulator dhcR is
divergently transcribed (71). Organization of operons and names of
phenylalanine/tyrosine catabolism genes vary in different organisms, including in other
Pseudomonas species (50).
Several proteins have been implicated in the regulation of phenylalanine/tyrosine
catabolism in various organisms, including Crc, TyrR/PhhR, and HmgR. Both global and
operon specific regulators have been identified that control phenylalanine/tyrosine
catabolism, which may be important in pyomelanin production. Regulators found in
Pseudomonas species will be discussed in the following sections.

1.4.1 Crc global regulator
Crc is a global regulator that controls expression of genes from aromatic
compound catabolism pathways. In P. putida and P. aeruginosa, Crc acts as a master
regulator of carbon metabolism (72). Studies in P. putida have shown that Crc
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Figure 1.2. Organization of genes for phenylalanine/tyrosine catabolism in P. aeruginosa. Operons
are formed for phhABC, hmgA-fahA-maiA, and dhcAB. phhR and dhcR are genes for regulatory
proteins of their respective operons. PA2010 is predicted to be a homolog of hmgR from P. putida,
which is a gene for a regulatory protein of the hmgA operon. Genes for regulatory proteins are in red.
P. aeruginosa nomenclature and PA numbers from PAO1 are used (Pseudomonas Genome Database
http://www.pseudomonas.com). Arrow size and distance between genes is not drawn to scale.
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represses expression of hpd, hmgA, and mai, which was indicated by increased mRNA
levels for those genes in a crc mutant compared to the wild type strain (72). As Crc is
not known to bind DNA, it is unknown if Crc affects transcription of the genes it
regulates directly or indirectly (72). Conflicting reports about the binding target for Crc
have been reported. In one study, Crc from P. putida was found to bind to mRNA and
repress translation (73), while a later study showed that Crc from P. aeruginosa did not
bind to RNA (74). Crc appears to be an important regulator of gene expression in P.
putida, and it is likely that similarities exist in P. aeruginosa. Additionally, in a
pyomelanogenic P. aeruginosa strain, a crc transposon mutant showed reduced
pyomelanin production (57), which indicates that Crc may have a role in pigment
formation by regulating expression of genes involved in tyrosine catabolism.

1.4.2 TyrR and PhhR transcriptional regulators
Another regulator for phenylalanine/tyrosine catabolism genes is TyrR/PhhR. In
E. coli, TyrR acts as both a repressor and an activator of DNA transcription. To activate
transcription, TryR interacts with the C-terminal region of the α-subunit of RNA
polymerase (αCTD) when aromatic amino acids are present and binds to DNA
upstream of the promoters for genes that encode aromatic amino acid transporters (75).
In E. coli, TyrB is an aromatic amino acid aminotransferase involved in the biosynthesis
of tyrosine and phenylalanine (76). TyrR represses tyrB transcription in the presence of
tyrosine or phenylalanine. TyrR forms hexamers in the presence of tyrosine, which bind
to DNA and prevent open complex formation during initiation of transcription (76). When
phenylalanine is present, TyrR dimers or tetramers bind to DNA and an open complex

17

can form, but RNA polymerase cannot exit the promoter (76). Both of these
mechanisms of repression prevent tyrB transcription. The Pseudomonas TyrR homolog
is PhhR (77), which has similar regulatory functions in both P. putida and P. aeruginosa,
with a few differences.
PhhR is a global regulator in P. putida that activates genes for phenylalanine
degradation (53). In both P. aeruginosa and P. putida, PhhR induced the phhA, hpd,
hmgA, and dhcA (PP3122 in P. putida) transcriptional units in response to
phenylalanine (52, 53, 77). Additionally, the expression of phenylalanine/tyrosine
catabolism genes was downregulated in a phhR mutant strain compared to the wild type
strain (52, 53). phhR expression was also induced in the presence of aromatic amino
acids, and P. putida PhhR appeared to negatively regulate phhR gene expression (52,
53). These results show that PhhR is necessary for transcription of genes involved in
phenylalanine/tyrosine catabolism, and aromatic amino acids are necessary for
induction of gene transcription. In addition, a phhR transposon mutant in a P.
aeruginosa pyomelanin producer showed abolishment of pigmentation (57), which
indicates a functional role for PhhR in pyomelanin production. This is likely due to
downregulation of phenylalanine/tyrosine catabolism gene expression in phhR mutants,
which could prevent pigment production because the pyomelanin precursor molecule
HGA would not be produced.
Experimental evidence has shown that PhhR binds to the phhA, hpd, and dhcA
(PP3122) promoters in P. aeruginosa and P. putida, and also to the hmgA promoter in
P. putida, but not in P. aeruginosa (52, 53). The experimental data for PhhR promoter
binding matches the predictions for PhhR binding sites in the promoters of those
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transcriptional units. Additionally, in P. aeruginosa it was found that PhhR mainly
regulates transcription from σ54 promoters, not σ70 promoters as seen in E. coli TyrR
(52, 77). Potential σ54 binding sites were identified in P. aeruginosa upstream of phhA,
hpd, and dhcA, but not hmgA (52), which corresponds with the identification of PhhR
binding sites upstream of the same genes and provides further evidence that those
transcriptional units are regulated by PhhR.
Additional differences between PhhR from P. putida and P. aeruginosa have
been identified. In P. putida, genes for aromatic amino acid biosynthesis were
repressed in the presence of phenylalanine (53). In P. aeruginosa, PhhR did not control
expression of biosynthesis genes for aromatic amino acids (52). Overall, there are many
similarities between PhhR from the closely related species P. aeruginosa and P. putida,
but there are some differences.

1.4.3 HmgR transcriptional repressor
A third regulator for tyrosine catabolism genes is HmgR. HmgR is an IclR-type
regulator that functions as a repressor for hmgABC gene expression in P. putida, and
the homologous protein PA2010 has been identified in P. aeruginosa (50). Studies of
HmgR function have shown that the protein binds to the hmg promoter in a region that
partially overlaps the ribosome binding site for hmgA to repress transcription of
hmgABC in the absence of HGA (50). HGA inhibited HmgR binding to the hmg
promoter, and a hmgR mutant strain constitutively produced HmgA in normal amounts
(50). These studies show that HmgR is important for repression of hmgABC gene
expression in P. putida, and is likely to be important in P. aeruginosa as well, as the
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hmgA promoter in P. aeruginosa contains a potential HmgR binding site (52). Because
P. putida and P. aeruginosa are closely related organisms, it is expected that HmgR
would have a similar function in P. aeruginosa.
HmgR repression can potentially explain PhhR regulation of hmgA. As described
above, PhhR regulated hmgA expression in P. aeruginosa, but there was no PhhR
binding site (52). This phenomenon can be explained by the presence or absence of
Hpd and HGA in the cell, as well as the HmgR binding site in the hmgA promoter. Since
hpd expression is controlled by PhhR, if PhhR activates hpd when phenylalanine is
present, the Hpd protein will be produced and HGA will subsequently be formed (52).
HGA can then bind to HmgR, which prevents HmgR from binding to the hmgA
promoter, and finally allows for expression of hmgA (52). PhhR indirectly regulates
hmgA expression through HmgR in P. aeruginosa, which adds to the complexity of
regulation of phenylalanine/tyrosine catabolism gene expression, and also pyomelanin
production. Interestingly, in P. putida, both PhhR and HmgR directly regulate hmgA
expression, as binding sites for both regulators have been identified in the promoter for
hmgA and experiments have shown regulation of hmgA transcription by PhhR and
HmgR. This demonstrates that there can be differences in regulation by two closely
related species.

1.5

Functions of pyomelanin
Microbes encounter a variety of conditions in their natural habitats, so it is

necessary to have mechanisms that will allow them survive variations in the
environment. One of these mechanisms is to produce pigments, such as pyomelanin.
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Pyomelanin has several functions that may help bacteria or fungi survive in host
organisms or the environment. These functions will be discussed in detail in the
following sections.

1.5.1 Protection from oxidative and UV stress
Pyomelanin provides protection from oxidative stress in some bacterial and
fungal species. In P. aeruginosa, pyomelanin protected cells from H2O2 induced
oxidative stress in both a plate based assay and a viable count assay (56, 58).
Additionally, P. aeruginosa pyomelanin containing supernatant was able to protect nonpigmented wild type cells from H2O2 (56). Pyomelanin produced by P. aeruginosa was
also able to protect cells from photodynamically induced oxidative stress, which can
generate singlet oxygen, superoxide anion radical, H2O2, and hydroxyl radical, by
scavenging radicals and quenching singlet oxygen (78). These results demonstrate that
pyomelanin produced by P. aeruginosa is able to provide protection from oxidative
stress under a variety of different test conditions, which is important because bacteria
may encounter different conditions in the various environments they inhabit.
Other bacterial and fungal species have also demonstrated resistance to
oxidative stress when pyomelanin was present. In V. campbellii, pyomelanin containing
supernatant was able to protect non-pigmented wild type cells from H2O2 induced
oxidative stress (63); this protective effect was also seen in P. aeruginosa. Nonpigmented strains of B. cenocepacia were more sensitive to H2O2 in a disc diffusion
assay, as well as to extracellular superoxide generated by the xanthine/xanthine
oxidase reaction, compared to strains that produced pyomelanin (36). In A. fumigatus,
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pyomelanin producers were more resistant to H2O2 induced oxidative stress than nonproducers in an agar plate diffusion assay (47). Pyomelanin provided protection from
both oxygen and nitrogen derived oxidants in Sporothrix sp. (48). In B. anthracis,
however, pyomelanin did not provide protection from oxidative stress in a H2O2 disc
diffusion assay, or when a non-pigmented strain was suspended in supernatants from a
pyomelanin producer followed by exposure to H2O2 (41). These results show that
pyomelanin frequently provides protection from oxidative stress in bacteria and fungi,
but this protection is not universal in all organisms that produce pyomelanin.
Additionally, pyomelanin can provide resistance to UV stress that may be
encountered by bacteria and fungi in the environment. In B. anthracis, pyomelanin
producers showed increased survival compared to non-pigmented strains after UV
irradiation (41). L. pneumophila with a mutation in the hpd homolog lly, which eliminated
pyomelanin production in the bacteria, was more sensitive to light than a pigmented
strain (66). In Sporothrix sp., pyomelanin production provided protection from UV light
(48). The ability of pyomelanin to protect against UV stress is important because UV
radiation can cause mutations in DNA that can be detrimental for the organism if they
cannot be repaired (79). These results show that pyomelanin can protect bacteria and
fungi from stresses they may encounter in the environment, whether it is in a host
during infection (oxidative stress) or in the natural environment (UV stress), which could
be detrimental for their survival.
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1.5.2 Iron reduction and acquisition
Pyomelanin also functions in electron transfer and metal reduction. Studies in S.
algae BrY have shown that pyomelanin can act as a soluble electron shuttle for iron
oxide reduction and as a terminal electron acceptor (40). S. algae BrY cells that
produced pyomelanin, as well as non-pyomelanogenic cells with added pyomelanin,
were able to reduce more ferric oxide than cells that did not produce pyomelanin (80).
These results indicate that it is the presence of pyomelanin that is important for
increased iron reduction, not necessarily the ability of the organism to produce
pyomelanin itself. In L. pneumophila, pyomelanin had ferric reductase activity (39). A
hmgA mutant that produced increased amounts of pyomelanin had higher ferric
reductase activity than wild type L. pneumophila, which produced low levels of
pyomelanin, while a lly mutant (hpd mutant) that was null for pyomelanin production had
lower ferric reductase activity than wild type (39). This data indicates that increased
amounts of pyomelanin production resulted in increased iron reduction.
Pyomelanin is also involved in iron uptake, as well as enhancement of bacterial
growth in low iron conditions. Studies of pyomelanin in L. pneumophila have shown that
both pyomelanin and the pyomelanin precursor molecule HGA are involved in iron
reduction, and the bacteria can take up the reduced iron (81). Pyomelanin also
increased growth of L. pneumophila in low iron conditions, which was likely due to the
association of iron with pyomelanin, which could lead to increased iron assimilation (81).
L. pneumophila also produces siderophores for acquiring iron, and a hyperpigmented
hmgA transposon mutant produced lower levels of siderophores than the wild type,
while a siderophore mutant produced more pyomelanin than wild type, which indicates
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that pyomelanin is involved in iron assimilation (81). These data demonstrate that L.
pneumophila has different methods for acquiring iron, and if one mechanism is inactive,
the other mechanism can compensate. Although it has not been tested in P.
aeruginosa, it is possible a similar mechanism for acquiring iron could exist in that
organism since it is capable of producing both pyomelanin and siderophores.
Enzymes involved in pyomelanin production are also affected by iron
concentrations. In L. pneumophila, PhhA was involved in pyomelanin production and
growth in low tyrosine media (69). PhhA has an iron cofactor in its active site and its
enzymatic activity required iron, but high concentrations of iron also inhibited activity
(69). In S. algae BrY the rate of pyomelanin production and the amount of pyomelanin
produced decreased when iron concentrations were higher than the optimum (82).
These results demonstrate that iron is necessary for pyomelanin production and that
pyomelanin itself is capable of providing bacteria with iron needed for growth and other
functions. The concentration of iron is important, however, since the presence of too
much iron can inhibit enzymatic function.

1.5.3 Antibiotic resistance
Resistance to antibiotics and other antimicrobial drugs can be a major problem
when treating bacterial and fungal infections. Various studies have shown that melanin
can bind to some antibiotics and antifungal drugs, thereby reducing the activity of those
drugs (26). Isotherm analysis of gentamicin and synthetic melanin revealed high levels
of binding between those compounds (83). Additionally, interactions between
tobramycin and synthetic melanin resulted in a decrease in antibiotic activity under
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certain conditions (84). Increased resistance to specific antibiotics was observed in
pyomelanogenic Stenotrophomonas maltophilia compared to non-pigmented strains
(85). In Sporothrix sp., pyomelanin production resulted in increased resistance to the
antifungal antibiotic amphotericin B (48). In a second study in Sporothrix sp.,
pyomelanin provided protection from the antifungal drug terbinafine during a time-kill
assay (86). These studies all reveal a role for melanin in antimicrobial resistance.
In P. aeruginosa, it was reported that pyomelanin producing strains were more
sensitive to antibiotics than non-pyomelanogenic strains (24, 25, 87). In these studies,
several different classes of antibiotics were tested, including aminoglycosides, βlactams, and polymyxins. These data conflict with the studies presented above that
showed reduced efficacy of antimicrobials in the presence of both synthetic melanin and
pyomelanin.
Recent studies in P. aeruginosa, however, reported no differences in sensitivity
to aminoglycoside, cephalosporin, β-lactam, and fluoroquinolone antibiotics in
pyomelanin producers compared to non-producers (56, 58). In A. baumannii,
pyomelanogenic clinical isolates were resistant to antibiotics, and treatment with
sulcotrione, an inhibitor of the tyrosine catabolism pathway, reduced pigment production
but this reduction in pigment production had no effect on antibiotic resistance (43).
These results show that pyomelanin production in A. baumannii, like P. aeruginosa,
does not appear to have an effect on antibiotic resistance.
These conflicting reports about the effects of pyomelanin and other types of
melanin on antibiotic sensitivity make it difficult to draw conclusions. Taken together,
these results suggest that pyomelanin production has little effect on antibiotic resistance
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in bacteria, but may have an effect on antibiotic resistance in fungi. A limitation of
antibiotic sensitivity assays is that many of them are performed by broth microdilution,
which uses diluted bacterial cultures, so little preformed pyomelanin may be present at
the start of the assay, which could affect the results if one wants to determine the
effects of pyomelanin on antibiotic resistance. Broth microdilution may show that
pyomelanin has no effect on antimicrobial resistance when there could actually be
resistance if a different type of assay, such as a time-killing assay, was performed. In a
time-killing assay, microbes are exposed to 2x minimum inhibitory concentration (MIC)
of antimicrobial agents and viable counts are determined at several time points (86).
This type of assay could potentially allow the researcher to start with higher levels of
preformed pyomelanin at the beginning of the assay, which may have an effect on the
antibiotic resistance results.

1.5.4 Infection persistence and virulence
Pyomelanin may also contribute to microbial infection persistence. Pyomelanin
and HGA have the ability to release iron from iron chelates that occur in a mammalian
host, including ferritin and transferrin, or in the environment, such as ferric hydroxide
(81). The ability to obtain iron from the environment may be important in bacterial
persistence during infection since iron is necessary for bacterial growth. Many metabolic
pathways and cellular functions require iron (88), including the PhhA, Hpd, and HmgA
enzymes involved in phenylalanine/tyrosine catabolism that have an iron cofactor in the
active site of the enzyme.

26

Melanin is also known to scavenge superoxide anion produced by macrophages
(37). Pyomelanin producing B. cenocepacia showed reduced trafficking to RAW 264.7
lysosomes compared to a non-pigmented strain (36), which suggested that the bacteria
may be persisting inside the phagocyte. Additionally, in A. fumigatus, transcription of
tyrosine catabolism genes was induced in response to human neutrophils, which
suggested that pyomelanin could be involved in immune system escape and fungal
survival in humans (35). The potential ability of pyomelanogenic microbes to obtain iron
from host iron chelates, scavenge ROS, reduce trafficking to lysosomes, and induce
transcription of tyrosine catabolism genes suggest that pyomelanin may play a role in
bacterial persistence during infection of phagocytes.
Finally, in a chronic mouse model of infection, pyomelanin producing P.
aeruginosa exhibited increased persistence compared to the non-pigmented wild type
strain (56). A mouse model of acute infection showed that pyomelanogenic P.
aeruginosa had increased persistence compared to non-pigmented wild type (60). It is
possible that some of the mechanisms described above were used to allow the bacteria
to persist in the mouse infection models; however, that remains to be tested since the
mechanism for bacterial persistence was not identified in the mouse studies. In L.
pneumophila, however, pyomelanin was not involved in intracellular survival of bacteria
in the amoeba host Hartmannella vermiformis (66), which indicates that pyomelanin
production is not always involved in infection persistence. These differences in bacterial
persistence in host organisms could be due to the differences in mammalian and
amoeba hosts.
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Several studies, however, have shown that pyomelanin can have a variable
effect on virulence. In a Caenorhabditis elegans virulence assay, pyomelanogenic P.
aeruginosa was more virulent than non-pigmented wild type (60). In B. anthracis,
pyomelanin production did not affect expression of virulence genes (41), which
demonstrates the potential for a pyomelanin producer to exhibit normal virulence traits.
Tyrosine degradation genes were upregulated in a mouse infection model, but
pyomelanin did not appear to have a role in pathogenicity or virulence in A. fumigatus
(35). Decreased virulence (approximately 2.7 fold) was seen for a V. campbellii
pyomelanin producer with an in-frame deletion in hmgA in a shrimp virulence model, as
well as downregulated expression of quorum sensing and bioluminescence genes (63).
Additionally, decreased virulence by a P. aeruginosa pyomelanin producer was
observed in an acute mouse model of infection (56). Overall, pyomelanin may have
some impact on virulence during bacterial and fungal infections, but the studies
presented above demonstrate that this impact could be microbial species or
experimental assay dependent.
Infection persistence and virulence are different but related phenomena in
microbes. Persistence can be defined as the ability of the microbe to survive longer in a
host organism than another microbe. It can also mean that the microbe has higher
numbers of cells than another microbe in a host over a specific time frame. Virulence is
related to the ability of the microbe to infect a host organism, since a microbe can
produce virulence factors to increase its ability to cause infection. Virulence can also be
implicated in microbial killing of the host because a more virulent microbe may cause
higher mortality of a host than a less virulent microbe. Additionally, in P. aeruginosa,
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virulence may actually decrease as an infection switches from acute to chronic (89).
This ability to downregulate virulence demonstrates that there is interplay between
virulence and persistence in microbial infections, and that there may be advantages to
persistence over virulence or vice versa, depending on the situation.

1.6

Anti-virulence treatment and NTBC
Bacteria are becoming more resistant to antimicrobial agents such as antibiotics,

which is a significant problem as most bacterial infections are treated with antibiotics.
Additionally, very few new antibiotics have been developed in recent years. As an
alternative to treating infections with antibiotics, anti-virulence therapies that target
microbial virulence factors are being investigated. Anti-virulence therapy targets
mechanisms that are beneficial for pathogen interactions with the host, instead of
targeting functions that are necessary for basic metabolism, which should increase the
specificity of the therapy for pathogens over the normal flora in the host (90). Good
targets for anti-virulence therapy include mechanisms involved in bacterial adhesion to
cells and colonization, secretion of cell surface proteins, regulatory bacterial functions
such as quorum sensing, cell wall components such as LPS, and pigments (19, 90).
When selecting a virulence factor for anti-virulence therapy, it is ideal if the target is
conserved in many species (90) so there is potential for broad application of the
therapy.
Microbial pigments can contribute to disease pathogenesis, due to the fact that
pigments can interfere with host immune clearance and can have proinflammatory or
cytotoxic properties (91). This can confer a survival advantage for the bacteria when
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they are in the host. This makes pigments, such as pyomelanin, good targets for antivirulence therapy. Since pyomelanin is conserved in a variety of bacterial and fungal
pathogens there is potential for broad application of an anti-virulence therapy targeting
that pigment. Additionally, pyomelanin production and a functional
phenylalanine/tyrosine catabolism pathway are not essential in bacteria, as indicated by
unimpaired growth of pathway mutants. This makes it less likely for resistance to
develop to an anti-virulence therapy targeting pyomelanin. Recently, pyomelanin
production in L. pneumophila was inhibited by a compound that targeted phenylalanine
hydroxylase (92). Another recent study showed that pyomelanin production in P.
aeruginosa could be inhibited by 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3cyclohexanedione (NTBC) treatment, which targets Hpd, and this pigment inhibition led
to increased sensitivity to oxidative stress (58). These results demonstrate that there is
interest in investigating different compounds that inhibit pyomelanin production.
NTBC was originally developed as an herbicide and binds to Hpd irreversibly at
its active site, which contains an iron center (93). The active form of Hpd contains a
ferrous center in the C-terminal domain, and binding of NTBC prevents oxidation of the
active site (51), thereby inhibiting Hpd function. NTBC has been developed as a
treatment for type I tyrosinemia (94). Type I tyrosinemia is caused by the lack of
fumarylacetoacetase (FahA) in the tyrosine catabolism pathway, which causes the
accumulation of toxic metabolites such as fumarylacetoacetate, leading to cirrhosis and
cancer of the liver (95). NTBC inhibition of Hpd activity prevents the accumulation of
toxic metabolites and progression of disease in type I tyrosinemia (94). NTBC treatment
will also inhibit the formation of HGA, thereby preventing pyomelanin production.
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Treatment of pyomelanin producing bacteria with NTBC is a novel application for
an already existing drug that has received FDA approval for treatment of type I
tyrosinemia in humans (51). Pyomelanin producing bacteria become more sensitive to
oxidative stress if pigment production is reduced or abolished, which can be achieved
through NTBC treatment (58). Increased sensitivity to oxidative stress via reduced
pigmentation is anticipated to increase immune cell mediated killing of bacteria and
thereby result in increased clearing of infections by the host immune system. Therefore,
bacterial or fungal infections by pyomelanogenic organisms may exhibit reduced
persistence after treatment with NTBC, demonstrating the potential for NTBC as an antivirulence therapy.

1.7

Concluding remarks
Pyomelanin production in bacteria and fungi is caused by a defect in

phenylalanine/tyrosine catabolism. This pathway is non-essential in microbes, as
demonstrated by unimpaired growth of pathway mutants, but it does allow microbes to
use phenylalanine and tyrosine as energy sources. One of the most common defects
resulting in pyomelanin production is a loss of HmgA function. Pyomelanin production is
regulated by global and operon specific regulators that can repress or activate gene
transcription. Importantly, pyomelanin has several functions that allow microbes to
survive in different environments, including resistance to oxidative and UV stress, and
iron reduction and acquisition. The effects of pyomelanin on antibiotic resistance,
infection persistence, and virulence have shown variability depending on the microbe
tested and experimental assay conditions.
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Since pyomelanin has functions that may contribute to pathogenesis and is
conserved in several pathogenic bacteria and fungi, we investigated NTBC, which is a
known inhibitor of the tyrosine catabolism pathway, as a potential anti-virulence therapy
for P. aeruginosa infections. In our studies, we examined mechanisms of pyomelanin
production in clinical isolates of P. aeruginosa from both acute and chronic infections.
We also determined the inhibitory effect of NTBC on pyomelanin production and
subsequent sensitivity to oxidative stress and aminoglycoside antibiotics. Additionally,
we determined mechanisms for inherent NTBC resistance in clinical isolates of P.
aeruginosa. Finally, we performed infection assays of the RAW 264.7 murine
macrophage-like cell line by pyomelanogenic and non-pyomelanogenic strains of P.
aeruginosa to determine the effects of pyomelanin on bacterial survival during infection.
Our experiments show that NTBC has potential as an anti-virulence therapy, but
additional studies must be performed.
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2.1

Introduction
Pseudomonas aeruginosa is an environmental bacterium that is capable of

causing both acute and chronic infections in compromised patients. This organism is
extremely adaptable, has a high level of intrinsic antibiotic resistance, a wide range of
virulence factors, and the ability to form biofilms (reviewed in (1)). Antibiotics are an
essential part of treating P. aeruginosa infections, but the inherent resistance combined
with emerging resistance due to selective pressure limits the therapeutic options
available. As a new strategy to combat infectious disease, the specific inhibition of
virulence factors has been proposed as an alternate treatment mechanism (2). By
attenuating bacterial virulence without targeting essential bacterial pathways, it may be
possible to aid in the clearing of infections while minimizing selective pressures that
perpetuate resistance.
Pyomelanin, a dark brown/black pigment is a potential target for anti-virulence
compounds. Pyomelanin production has been reported in P. aeruginosa isolates from
urinary tract infections and chronically infected cystic fibrosis (CF) patients (3, 4).
Pyomelanin is one of many forms of melanin that is produced by a wide variety of
organisms. Production of pyomelanin is reported to provide a survival advantage,
scavenge free radicals, bind various drugs, give resistance to light and reactive oxygen
species, and is involved in iron reduction and acquisition, and extracellular electron
transfer (4-9). A number of environmental and pathogenic bacteria have been reported
to produce this pigment (3, 8, 10-14). In Shewanella oneidensis and S. algae,
pyomelanin plays a role in biogeochemical cycling of metals, as pigment production
enhances hydrous ferric oxide reduction and electron transfer (15-17). In Legionella
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pneumophilia, pigment production may contribute to pathogenesis as pyomelanin
mediates ferric reduction from ferritin and transferrin (8). Non-pyomelanogenic strains of
Burkholderia cepacia are more sensitive to externally generated oxidative stress and
show reduced survival in phagocytic cells (11). In P. aeruginosa pyomelanin production
results in increased persistence and virulence in mouse infection models (3).
Pyomelanin is a negatively charged extracellular pigment of high molecular
weight, derived from the tyrosine catabolism pathway (6, 18, 19). 4hydroxyphenylpyruvate is converted to homogentisate (HGA) by 4hydroxyphenylpyruvate dioxygenase (Hpd) (Figure 2.1). HGA is then converted to 4maleylacetoacetate by homogentisate 1,2-dioxygenase (HmgA). A loss of HmgA activity
leads to the accumulation of HGA, which is secreted via the ABC transporter
HatABCDE. Defects in either the ATP-binding cassette or the permease components of
this transporter result in reduced pyomelanin production (4). Once secreted from the
cell, HGA auto-oxidizes and self-polymerizes to form pyomelanin. Both point mutations
in hmgA and chromosomal deletions have been reported in clinical P. aeruginosa
isolates producing pyomelanin (3, 10).
Hpd activity is essential for the synthesis of HGA, and ostensibly irreversible
binding with 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione (NTBC) inhibits
Hpd activity of Streptomyces avermitilis in vitro (20). Although it was originally
developed as a herbicide, NTBC is a FDA approved treatment for type I tyrosinemia
(21). Type I tyrosinemia is the result of a defect in the tyrosine catabolism pathway,
which causes the accumulation of toxic metabolites such as fumarylacetoacetate,
leading to cirrhosis and cancer of the liver (22). Binding of NTBC to Hpd prevents the
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L-tyrosine
PhhC
4-hydroxyphenylpyruvate
NTBC

Hpd
HatABCDE

homogentisate (HGA)

Pyomelanin

Secretion, autooxidation, & selfpolymerization

HmgA
4-maleylacetoacetate
MaiA
4-fumarylacetoacetate
FahA
4-fumarate

acetoacetate

Figure 2.1. Tyrosine catabolism pathway of Pseudomonas aeruginosa. Inactivation of HmgA results in
the secretion of HGA, which auto-oxidizes and self-polymerizes to form pyomelanin. NTBC inhibits
HGA production and pyomelanin formation through interactions with Hpd.
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accumulation of toxic metabolites and disease progression (21). We report here on
NTBC treatment of pyomelanogenic strains of P. aeruginosa, the resulting reduction in
pyomelanin production, and the corresponding increase in sensitivity to oxidative stress.

2.2

Materials and Methods

2.2.1 Bacterial strains and growth conditions
Laboratory strains of P. aeruginosa PAO1 (obtained from Carrie Harwood,
University of Washington), transposon mutants hpd::tn (PW2577) and hmgA::tn
(PW4489) and the clinical isolate PA1111 (obtained from Dara Frank, MCW) were
grown at 37°C in LB supplemented with tetracycline (60 µg/ml) and gentamicin (50
µg/ml) as appropriate. The transposon mutants were obtained from the University of
Washington transposon mutant collection (23). Escherichia coli DH5α (NEB) was used
as a host for recombinant plasmids, and was grown in LB with gentamicin (10 µg/ml) as
appropriate.

2.2.2 Chemicals
NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione), H2O2, and
tobramycin were purchased from Sigma-Aldrich. Gentamicin and kanamycin were
purchased from Gold Bio and Fisher Scientific, respectively.

2.2.3 HmgA overexpression
hmgA (PA2009) was amplified from the PAO1 genome using primers hmgAfor (5’
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GGTCTAGAATGAACCTCGACTCCACTGC 3’) and hmgArev (5’
CCGAGCTCTTATCTCCGTTGCGGGTTG 3’) and cloned into the XbaI and SacI sites of
pJN105 (24). The PCR product was sequenced to ensure no mutations were
introduced. The resulting plasmids were transformed into P. aeruginosa strains.
Following confirmation of transformation, HmgA expression was induced with arabinose
during overnight growth in LB supplemented with gentamicin.

2.2.4 RT-PCR
Strains were grown overnight until pigment production occurred in pyomelanin
producers. RNA was isolated from 5x108 cells using RNeasy Mini Kit (Qiagen) and
digested with DNaseI (Promega). RT-PCR was performed using OneStep RT-PCR Kit
(Qiagen) with equal concentrations of RNA for all strains tested. Primers were designed
to amplify 202 base pairs at the 5’ end of hpd, beginning with the start codon. The
following primers were used: hpD-RT-F (5’ ATGAACGCCGTGCCAAGATCG 3’) and
hpD-RT-R (5’ CGTTGAGCACGATGTTGATATC 3’). Primers used for the amplification
of 200 base pairs of 16S rRNA are as follows: 16S-RT-PCR-F (5’
GACTCCTACGGGAGGCAGC 3’) and 16S-RT-PCR-R (5’
GTATTACCGCGGCTGCTGGC 3’). Relative amounts of RT-PCR products were
estimated using ImageJ software.

2.2.5 Southern Hybridization
Chromosomal DNA was isolated from laboratory and clinical isolates of
Pseudomonas aeruginosa, digested with SalI, electrophoresed, and transferred to
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positively charged nylon membranes by a downward capillary transfer method (25). A
digoxigenin-labeled probe was generated through amplification of hmgA by PCR and
the incorporation of digoxigenin-UTP by random priming as recommended by the
manufacturer (Roche). Southern hybridizations were performed as previously described
(26).

2.2.6 Growth Curves
Overnight cultures were grown in LB + 300 µM NTBC or LB with the
corresponding amount of DMSO. The overnight cultures were diluted to OD600 0.05 in
LB + 300 µM NTBC or LB + DMSO, and the optical density was measured every hour.
Each sample was pelleted and resuspended in LB prior to the optical density reading to
ensure the results were not influenced by the presence of pyomelanin.

2.2.7 Oxidative stress assay
Overnight cultures were grown with NTBC (300 µM) or with a corresponding
volume of DMSO as a control. Optical densities (OD600) were measured using washed
cells, and cultures were diluted to equivalent OD600 values (~2.5). Ten-fold serial
dilutions were made in PBS containing either 300 µM NTBC or DMSO as appropriate. 5
µL of each serial dilution was spotted onto LB plates containing the indicated
concentration of H2O2. Laboratory strains were incubated for 24 h and PA1111 was
incubated for 45 h at 37°C.
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2.2.8 Determination of MICs
Minimal inhibitory concentrations (MICs) were determined by two-fold serial
microtiter broth dilution (27), using an inoculum of 2.75 x 105 CFU/ml. Inoculum
concentration was determined using washed cells to ensure that pyomelanin production
did not affect OD600 readings. NTBC was included in the appropriate wells at a final
concentration of 300 µM. MICs were recorded as the lowest concentration of antibiotic
inhibiting growth following 24 h of incubation at 37°C.

2.3

Results and Discussion

2.3.1 Pyomelanin production by a clinical isolate of P. aeruginosa.
PA1111, a pyomelanogenic clinical isolate from an acute infection was obtained
from Dara Frank (Medical College of Wisconsin). This strain lacked type III secretion
proteins but was cytotoxic in a tissue culture assay (28). To determine the cause of
pyomelanin production in this isolate, HmgA (PA2009) from PAO1 was expressed from
pJN105 (24). Following induction with 0.05% and 0.1% arabinose, pyomelanin
production was eliminated in hmgA::tn and PA1111 respectively (Figure 2.2A). P.
aeruginosa hmgA::tn functions as a positive control for pyomelanin production as hmgA
is interrupted with the ISphoA/hah transposon (23). P. aeruginosa PAO1 and hpd::tn
(isogenic to hmgA::tn) were included as negative controls; neither strain produces
pyomelanin.
Since increased amounts of arabinose were required to eliminate pyomelanin
production in PA1111 relative to hmgA::tn (compare 0.05 to 0.1%), we assayed hpd
transcript levels through RT-PCR (Figure 2.2B). Quantification of the relative levels
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Figure 2.2. HmgA expression alleviates pyomelanin production in lab and clinical isolates in a dose
dependent manner. A) The indicated P. aeruginosa strains containing either hmgA-pJN105 (+) or
pJN105 (-) were incubated overnight in LB + gentamicin (50 µg/ml) with the indicated concentrations
of arabinose. B) RT-PCR amplification of hpd transcript in PAO1, hmgA::tn, and PA1111. C) RT-PCR
amplification of 16S rRNA from PAO1, hmgA::tn and PA1111.
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revealed that in both PAO1 and PA1111 hpd transcript was approximately 10% more
abundant than in hmgA::tn. It is unlikely that this subtle increase in hpd transcript levels
is responsible for the residual pyomelanin production in PA1111 at low levels of
induction (0.05% arabinose). This suggests that the clinical isolate may have altered
translation or post-translational modification resulting in increased expression or activity
of Hpd.
The ability to abolish pyomelanin production in PA1111 through expression of
wild type HmgA suggested that either a chromosomal deletion or inactivation of the
hmgA gene occurred, both of which have been reported in clinical isolates of P.
aeruginosa (3, 10). A third reported cause of pyomelanin production is imbalanced
enzyme expression within the L-tyrosine catabolism pathway. In Vibrio cholerae (ATCC
14035), homogentisate dioxygenase and the downstream enzymes are expressed at
lower levels than hydroxyphenylpyruvate dioxygenase, leading to an accumulation of
HGA and pyomelanin production (29). To determine the genetic cause of pyomelanin
production in PA1111, we attempted to PCR amplify and sequence hmgA. Despite
repeated attempts, we were unable to amplify hmgA via colony PCR. To verify these
results, Southern hybridization was performed with DIG-labeled hmgA as a probe. No
hybridization was detected between the hmgA probe and the PA1111 genome (Figure
2.3). This, combined with our ability to complement the pyomelanin phenotype via
induction of hmgA expression, suggests that a chromosomal deletion has occurred.
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Figure 2.3. PA1111 has a chromosomal deletion of hmgA. A) Schematic for predicted band sizes with
SalI digestion of genomic DNA from PAO1, hpd::tn, and hmgA::tn. Blue, chromosomal DNA upstream
and downstream from hmgA; red, hmgA; green, phoA transposon (tn) in hmgA. B) Southern blot
hybridization of DIG-hmgA probe to SalI digested DNA from PAO1, hmgA::tn, PA1111, and hpd::tn.
Bands at the predicted sizes were seen for PAO1, hmgA::tn, and hpd::tn. PA1111 showed no
hybridization with DIG-hmgA, indicating that a chromosomal deletion of hmgA occurred. kbp, kilo base
pairs.
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2.3.2 NTBC inhibits pyomelanin production in P. aeruginosa without disrupting
growth.
NTBC is known to bind Hpd (4-hydroxyphenylpyruvate dioxygenase) and inhibit
the conversion of 4-hydroxyphenylpyruvate to homogentisate (20). We, therefore,
assayed NTBC treatment for disruption of pyomelanin production in P. aeruginosa. The
two pyomelanin producing strains (hmgA::tn and PA1111) were grown overnight with
increasing amounts of NTBC. Following overnight growth, inhibition of pyomelanin
production was determined visually (Figure 2.4A). NTBC (300 µM) inhibited pyomelanin
production in hmgA::tn, while PA1111 required higher concentrations of NTBC to inhibit
pyomelanin production (900 µM). Sequencing of hpdPA1111 revealed two silent mutations
upon comparison with hpdPAO1 (PA0865), demonstrating that mutations within Hpd were
not responsible for the residual PA1111 pyomelanin production in the presence of 300
µM NTBC. To ensure that NTBC did not alter the growth of P. aeruginosa, we measured
the optical densities of cultures grown in the presence and absence of NTBC. The
laboratory strains and PA1111 grew at the same rate in the presence or absence of 300
µM NTBC (Figure 2.4B), indicating that the reduction in pigmentation was not due to
altered growth rates.

2.3.3 NTBC treatment of pyomelanogenic strains does not alter aminoglycoside
MICs.
It has been reported that melanin has the ability to non-specifically bind a number
of diverse compounds. Isotherm analysis indicated that gentamicin had a high level of
binding to synthetic melanin through a series of diverse interactions (30). Melanin52
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Figure 2.4. NTBC treatment inhibits pyomelanin production without affecting growth. A) Pyomelanin
production by P. aeruginosa with and without NTBC treatment. Laboratory and clinical strains were
grown overnight with the indicated concentrations of NTBC. B) Growth curves of laboratory and
clinical strains of P. aeruginosa with and without 300 µM NTBC treatment. Strains grown without
NTBC are indicated with closed symbols, while those grown with NTBC are indicated with open
symbols. Wild type PAO1 (diamonds), hpd::tn (triangles), hmgA::tn (squares), PA1111 (circles). The
growth curves are compiled from three independent experiments, with error bars indicating standard
error of the mean.
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tobramycin interactions have resulted in a decrease of antibiotic activity of 80% under
certain conditions (31). Aminoglycosides are positively charged at physiological pH,
which may contribute to the interactions with negatively charged melanin (6).
Furthermore, a significant correlation was seen between pyomelanin production in
Stenotrophomonas maltophilia and resistance to specific antibiotics (14). We therefore
assayed both pyomelanin producing and non-producing strains (with and without NTBC
treatment) to determine the minimal inhibitory concentrations (MICs) of
aminoglycosides.
Minimal inhibitory concentrations were determined by two-fold serial microtiter
broth dilution (27). Our results indicated that, under these conditions, the pyomelanin
producing strains (hmgA::tn and PA1111) did not show significantly higher
aminoglycoside MICs than the non-pyomelanin producing strains (PAO1 and hpd::tn,
Table 2.1). While treatment of the pyomelanin producing strains with NTBC did inhibit
pyomelanin production, the MICs remained unchanged. These data indicated that
neither pyomelanin production nor NTBC treatment affect the aminoglycoside MICs for
P. aeruginosa. This is in agreement with an earlier study wherein MICs were unaltered
by pyomelanin production (3), and provides further clarity to the discussion within the
literature regarding pyomelanin production and antibiotic resistance. Early studies of
pyomelanin production reported that pyomelanogenic P. aeruginosa isolates were more
sensitive to antibiotics when compared to non-pyomelanogenic strains (32). In contrast,
when Staphylococcus aureus was incubated in supernatant from pyomelanogenic P.
aeruginosa, the MIC values remained unchanged (33). When considering the results of
these studies it is critical consider the sources of the melanin; the isotherm analysis was

54

Table 2.1. Aminoglycoside MICs (µg/ml) of laboratory and clinical isolates of P. aeruginosa.

Three independent colonies were tested in triplicate for each strain.
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conducted with eumelanin (or synthetic melanin) generated from 3,4dihydroxyphenylalanine (DOPA), not pyomelanin generated from homogentisate (6). It
is possible that the discrepancy between our results and the isotherm studies is due to
differences in melanin structures (G. Moran, personal communication). While the S.
maltophilia studies did correlate pyomelanin production with increased resistance to
some β-lactam antibiotics and fluoroquinolones, resistance was not detected to either
gentamicin or trimethoprim/sulfamethoxazole (14). Importantly, a direct causal
relationship was not tested, and the authors acknowledged that these phenotypes could
have resulted from independent mutations.

2.3.4 NTBC treatment of pyomelanin producing P. aeruginosa increases
sensitivity to oxidative stress.
The antioxidant properties of pyomelanin are proposed to contribute to the
increased persistence and virulence of pyomelanogenic bacteria in infection models (3,
11, 12). Since pyomelanogenic strains of Burkholderia cepacia and P. aeruginosa have
increased resistance to hydrogen peroxide, we examined if NTBC treatment increased
sensitivity of pyomelanogenic strains of P. aeruginosa to oxidative stress.
The H2O2 spot plates showed that both pyomelanogenic strains (hmgA::tn and
PA1111) have increased resistance to hydrogen peroxide relative to the nonpyomelanogenic strains (PAO1 and hpd::tn) (Figure 2.5). Importantly, NTBC treatment
of pyomelanogenic strains resulted in increased sensitivity to 0.6 mM H2O2. This
illustrates the potential use of NTBC as an anti-virulence factor. The change in
sensitivity to H2O2 was smaller for PA1111 than hmgA::tn, and resulted in an
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Figure 2.5. NTBC treatment increases H2O2 sensitivity in pyomelanin producing strains. 10-fold serial
dilutions of the indicated strains were spotted onto LB plates containing the indicated concentrations of
hydrogen peroxide.

approximately 24% reduction in number of PA1111 colony forming units (based on 4
independent experiments). It is likely that the residual pyomelanin produced in PA1111
at 300 µM NTBC provides a small level of protection against oxidative stress compared
to hmgA::tn. As expected, NTBC treatment of either wild type PAO1 or hpd::tn did not
affect sensitivity to H2O2.
In this report, we determined that the pyomelanin production in a strain of P.
aeruginosa PA1111 isolated from an acute infection was likely due to the loss of HmgA
activity resulting from a chromosomal deletion (28). This phenotype has previously been
reported for CF isolates and has been shown to decrease clearance/increase
persistence in mouse models of chronic infection, suggesting that the development of
pyomelanin production may confer an adaptive advantage (3, 10). Given the antioxidant
properties of pyomelanin, it is likely that pigment production would provide protection
from oxidative stress in both chronic and acute infections.
This study has shown that NTBC treatment inhibited pyomelanin production by P.
aeruginosa, and in doing so increased the sensitivity of both laboratory and clinical
isolates to oxidative stress, as is found in the respiratory burst from macrophages and
monocytes. This suggests that NTBC, as an already FDA-approved compound, has
potential as an anti-virulence factor that could be used in combination with existing
antibiotics. Pyomelanin is made by a wide variety of organisms, and has been reported
in both chronic and acute infections. Given the number of organisms that produce
pyomelanin, its functions in iron acquisition and as an antioxidant, and the presence of
pyomelanin in both acute and chronic infections, there are a high number of potential
applications of NTBC as an anti-virulence factor.
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Chapter Three
Resistance to NTBC in the pyomelanogenic Pseudomonas aeruginosa
clinical isolate DKN343
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3.1

Introduction
Pyomelanin has several functions that are involved in helping bacteria and fungi

survive in host organisms or the environment. First, pyomelanin can provide protection
from oxidative stress and UV light (1-8). Additionally, pyomelanin is involved in electron
transfer, iron reduction, and iron acquisition (9-12). Studies have also shown that
pyomelanin may be involved in Pseudomonas aeruginosa infection persistence (2, 13).
Pyomelanin production in Vibrio campbellii has also been associated with reduced
virulence (14), which could allow for increased infection persistence.
Many clinical and environmental bacterial and fungal species have been reported
to produce pyomelanin, including P. aeruginosa, Burkholderia cepacia complex, Vibrio
cholerae, Legionella pneumophila, Shewanella algae, Bacillus anthracis, Aeromonas
media, Acinetobacter baumannii, Sinorhizobium meliloti, Streptomyces coelicolor,
Alteromonas stellipolaris, Aspergillus fumigatus, Sporothrix sp., and Penicillium
chrysogenum (4-7, 10, 12, 15-23). In these strains, pyomelanin is either naturally
produced in the wild type strain or is the result of a mutation or deletion of genes known
to be involved in pyomelanin production.
Pyomelanin is a negatively charged, extracellular, reddish-brown pigment derived
from the tyrosine catabolism pathway when homogentisate (HGA) is secreted from the
cell via the HatABCDE ABC transport system, auto-oxidized, and self-polymerized
(Figure 3.1) (2, 24-26). 4-hydroxyphenylpyruvate dioxygenase (Hpd) is required for
pyomelanin production as it converts 4-hydroxyphenylpyruvate into HGA. Inactivation of
hpd via deletion or transposon mutagenesis in pyomelanin producers eliminates
pigment production (5, 12, 26, 27). During the breakdown of tyrosine, HGA is converted
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Figure 3.1. Tyrosine catabolism pathway in P. aeruginosa. Pyomelanin is produced via inactivation of
HmgA, which results in secretion of HGA from the cell and subsequent auto-oxidation and selfpolymerization to form pigment. NTBC binds to Hpd to prevent formation of HGA and pyomelanin
production. PhhC, aromatic amino acid aminotransferase; Hpd, 4-hydroxyphenylpyruvate
dioxygenase; HmgA, homogentisate 1,2-dioxygenase; MaiA, maleylacetoacetate isomerase; FahA,
fumarylacetoacetase; HatABCDE, HatABCDE ABC transporter.
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into 4-maleylacetoacetate by homogentisate 1,2-dioxygenase (HmgA). Mutations that
result in loss of HmgA function lead to an accumulation of HGA and consequently
pyomelanin production (1, 2, 28). A relative reduction in enzyme activity in the latter part
of the tyrosine catabolism pathway (HmgA, MaiA, and FahA) compared to the upper
part of the pathway can also lead to pyomelanin production (29).
Bacteria are becoming more resistant to antibiotics, so investigation into new
antimicrobial agents is necessary. Anti-virulence therapy targets mechanisms that are
beneficial for pathogen interactions with the host, instead of targeting functions that are
necessary for basic metabolism (30). This allows the therapy to have specificity for
pathogens over the normal flora in the host (30). Since pyomelanin has several
functions that may be advantageous for bacterial or fungal survival in a host, and has
been reported to contribute to infection persistence, it is an ideal target for anti-virulence
therapy. We have previously shown that the Hpd inhibiting compound 2-(2-nitro-4trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) reduces pyomelanin production
in P. aeruginosa clinical isolates and increases sensitivity to oxidative stress (1). NTBC,
therefore, shows promise as an anti-virulence treatment.
P. aeruginosa is a Gram negative bacterium that is able to survive in a variety of
different ecological environments including soil, water, plants, and animals (31). This
organism is also an opportunistic pathogen that frequently colonizes the lungs of cystic
fibrosis (CF) patients, where it causes chronic infections by forming biofilms (32).
Additionally, it causes acute infections in burn patients (33, 34). P. aeruginosa is
capable of producing a variety of virulence factors including secreted proteins, toxins,
and pigments that may help the bacteria survive during infection (35).
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In our current study, we identified the mechanism of pyomelanin production in the
clinical P. aeruginosa isolate DKN343. DKN343 was previously reported to have a wild
type hmgA sequence, and expression of hmgA from a plasmid did not alleviate
pyomelanin production, which suggested that pyomelanin was produced via a different
mechanism than inactivation of HmgA (26). We found, however, a mutation in HmgA
that is predicted to render the enzyme non-functional causing a defect in tyrosine
catabolism and resulting in pyomelanin production. In addition, we discovered a high
level of pre-existing resistance to NTBC, which was mediated by the MexAB-OprM
multi-drug efflux pump.

3.2

Materials and Methods

3.2.1 Strains, plasmids, and growth conditions
Lists of strains and plasmids are found in Tables 3.1 and 3.2, respectively.
Strains were grown on LB agar or in LB broth supplemented with gentamicin,
tetracycline, or chloramphenicol where appropriate. Antibiotic concentrations were as
follows: gentamicin 10 µg ml-1 (E. coli), 50 µg ml-1 (hpd::tn, hmgA::tn, and DKN343 in
broth media), and 100 µg ml-1 (DKN343 on agar); tetracycline 10 µg ml-1 (E. coli) and
195 µg ml-1 (DKN343); chloramphenicol 5 µg ml-1. Strains were grown at 37°C unless
otherwise indicated.
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Table 3.1. Strains used in this study.
Strains
Description
P. aeruginosa PAO1
P. aeruginosa PAO1 (Iglewski
strain)
P. aeruginosa hpd::tn
PW2577, transposon mutant
with lacZ-tn inserted in hpd,
TcR, pyomelanin non-producer
P. aeruginosa hmgA::tn

PW4489, transposon mutant
with phoA-tn inserted in hmgA,
TcR, pyomelanin producer

P. aeruginosa DKN343

Clinical isolate of P. aeruginosa
from sputum sample,
pyomelanin producer
fhuA2 Δ(argF-lacZ)U169 phoA
glnV44 Φ80 Δ(lacZ)M15 gyrA96
recA1 relA1 endA1 thi-1 hsdR17
TpR SmR recA thi pro hsdR- M+
RP4 2-Tc::Mu-Km::Tn7 λpir
Strain for conjugating plasmids
In-frame deletion of hpd in
hmgA::tn
In-frame deletion of hpd in
DKN343
In-frame deletion of mexA in
hmgA::tn
In-frame deletion of mexA in
DKN343
In-frame deletion of PA0242 in
hmgA::tn
In-frame deletion of PA0242 in
DKN343

E. coli DH5α
E. coli S17-1
hmgA::tnΔhpd
DKN343Δhpd
hmgA::tnΔmexA
DKN343ΔmexA
hmgA::tnΔPA0242
DKN343ΔPA0242
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Source
Carrie Harwood
University of
Washington PAO1
transposon mutant
collection
University of
Washington PAO1
transposon mutant
collection
(26)
New England Biolabs
(36)
This study
This study
This study
This study
This study
This study

Table 3.2. Plasmids used in this study.
Plasmids
Description
pEX18Tc
Suicide vector for making deletion
mutants, TcR
pEX19Gm
Suicide vector for making deletion
mutants, GmR
Fusion fragment for hpd deletion
Δhpd-pEX18Tc
cloned into pEX18Tc at the BamHI
and HindIII sites
Fusion fragment for hpd deletion
Δhpd-pEX19Gm
cloned into pEX19Gm at the EcoRI
and HindIII sites, EcoRI site was
from pEX18Tc
Fusion fragment for mexA deletion
ΔmexA-pEX18Tc
cloned into pEX18Tc at the XbaI
and KpnI sites
Fusion fragment for mexA deletion
ΔmexA-pEX19Gm
cloned into pEX19Gm at the XbaI
and KpnI sites
Fusion fragment for PA0242
ΔPA0242-pEX18Tc
deletion cloned into pEX18Tc at the
SacI and HindIII sites
Fusion fragment for PA0242
ΔPA0242-pEX19Gm
deletion cloned into pEX19Gm at
the SacI and HindIII sites
pSB109
Derivative of pJN105 with an
enhanced ribosome binding site, 6xHis tag, GmR
hmgA-pSB109
hmgA from PAO1 cloned into
pSB109 at the NdeI and SacI sites
hmgAA306T-pSB109
hmgA from PAO1 with point
mutation for A306T
hmgAH330Y-pSB109
hmgA from PAO1 with point
mutation for H330Y
hpd-pSB109
hpd from PAO1 cloned into pSB109
at the NdeI and SacI sites
mexA-pSB109
mexA from PAO1 cloned into
pSB109 at the NdeI and SacI sites
PA0242-pSB109
PA0242 from PAO1 cloned into
pSB109 at the EcoRI and SacI sites
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Source
Carrie Harwood
Carrie Harwood
This study
This study

This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

3.2.2 Generation of deletion mutants
In-frame deletion mutants of hpd, mexA and PA0242 in P. aeruginosa were
constructed by splicing by overlap extension (SOE) PCR with PAO1 DNA as template.
Primers are listed in Table 3.3. The in-frame fusions were sequenced to ensure no
mutations were introduced. The deletion alleles were cloned into pEX19Gm or pEX18Tc
and transformed into E. coli S17-1 for mating with P. aeruginosa hmgA::tn and DKN343,
respectively. These constructs were introduced into P. aeruginosa by conjugation, and
merodiploids were selected on chloramphenicol and tetracycline or gentamicin as
appropriate and incubated overnight (hmgA::tn) or two days (DKN343) to isolate
merodiploids. Resolution of the merodiploids was achieved through 10% sucrose
counter selection. Following screening on tetracycline or gentamicin and sucrose, the
deletions were confirmed by PCR or Southern blot.

3.2.3 NTBC titrations
NTBC titrations were performed as previously described (37) with gentamicin and
arabinose supplementation where appropriate. NTBC (Sigma-Aldrich) was dissolved in
DMSO and stored at -20°C until use. Cultures were incubated for approximately 24
hours before photos were taken for analysis.
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Table 3.3. Primers used in this study.
Primer name
Primer Sequence (5’ – 3’)a,b
Primers for in-frame deletions
GTAGCGGATCCCGATGCCTGCCACCGGAC
Δhpd-up-For
GAGGCTGGCGGCAGCGGGACCGGCCTCCTCGTTGT
Δhpd -up-Rev
TC
GAACAACGAGGAGGCCGGTCCCGCTGCCGCCAGCC
Δhpd -dn-For
TC
CGCCGAAGCTTGCCGCGGTGAAGCCGAGC
Δhpd -dn-Rev
CCTCTAGACATCACCGGCAACCTGACCC
ΔmexA-up-For
CCCCTTGATCAGCCCTTGCTTCGTTGCATAGCGTTGT
ΔmexA -up-Rev
CCTC
GAGGACAACGCTATGCAACGAAGCAAGGGCTGATCA
ΔmexA -dn-For
AGGGG
GGGGTACCTACGGGTAGACCACCTTC
ΔmexA -dn-Rev
CCAAGAGCTCAACCACAGGCGGGTGGTC
ΔPA0242-up-For
GACAATTCTCACAGCTTGACACGCTGCATGCTTCGAC
ΔPA0242-up-Rev
TC
GAGTCGAAGCATGCAGCGTGTCAAGCTGTGAGAATT
ΔPA0242-dn-For
GTC
GTCCAAGCTTCCTGTGGGTCGCCGAGGTG
ΔPA0242-dn-Rev
Primers for gene sequencing
hmgA-external forward
CGATAAAAATAACGCAGCCAGC
hmgA-external reverse
GGTTTTGCAGGGGAAAGTCG
hpd-external forward
GGCATCTCCCATGTCGTCGGC
hpd-external reverse
GCCGCTGGAACGGAAACGC
Primers for complementation
hmgA-for-pSB109
GGCATATGATGAACCTCGACTCCACTGC
hmgA-rev
CCGAGCTCTTATCTCCGTTGCGGGTTG
hpd-for-pSB109
GGCATATGATGAACGCCGTGGCCAAG
hpd-rev
GGGAGCTCGGATCAGATCACGCCGCG
mexA-for-pSB109
CCCATATGATGCAACGAACGCCAGCC
mexA-rev
GGGAGCTCTCAGCCCTTGCTGTCGGTTTTC
PA0242-for-pSB109
GGGAATTCATGCAGCGTTCGATCGCC
PA02424-rev
GGGAGCTCATTCTCACAGCTTGACCC
Primers for site directed mutagenesis
hmgA-A306T-for
CAGCGTCCCCGGCCTGACCAACATCGACTTCGTG
hmgA-A306T-rev
CACGAAGTCGATGTTGGTCAGGCCGGGGACGCTG
hmgA-H330Y-for
CCGTCCGCCATGGTTCTACCGCAACCTGATGAACG
hmgA-H330Y-rev
CGTTCATCAGGTTGCGGTAGAACCATGGCGGACGG
a
Restriction enzyme sites are underlined.
b
Mutagenic codons are in bold.
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3.2.4 Sequencing of hmgA and hpd from DKN343
hmgA and hpd from DKN343 were PCR amplified using the appropriate primers
(Table 3.3), purified, and sequenced. The sequencing results were compared to P.
aeruginosa PA14 to identify any mutations.

3.2.5 Complementation studies
Plasmids for complementation were created by amplifying hmgA, hpd, mexA,
and PA0242 from PAO1 using the appropriate primers (Table 3.3). Gene fragments
were sequenced and cloned into pSB109. Plasmids were maintained in E. coli DH5α
and transformed into the appropriate P. aeruginosa strain. Strains containing pSB109
empty vector were used as controls. Test tubes containing LB and gentamicin were
inoculated with washed overnight cultures to a concentration of OD600 0.05 (hpd::tn and
hmgA::tn) or 0.1 (DKN343) and grown to OD600 0.2-0.3 before induction with arabinose
(0-0.5%) for 1.5 h. Whole cell lysates were separated by SDS-PAGE. The remaining
cultures were incubated for a total of 24 hours and photos were taken for analysis.

3.2.6 Site directed mutagenesis
Single point mutations of A306T and H330Y in hmgA were generated by site
directed mutagenesis. PCR was performed with the appropriate mutagenic primers
(Table 3.3) using the hmgA-pSB109 plasmid as template. The PCR product was
digested with DpnI (New England Biolabs) and transformed into DH5α cells. The
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plasmid DNA was sequenced to confirm the introduced mutation was present and
transformed into hmgA::tn for complementation studies as described above.

3.2.7 SDS-PAGE and Western blots
Whole cell lysates from complementation studies were analyzed by SDS-PAGE
on 10% gels. Proteins were transferred to PVDF and probed using mouse-α-His
antibody (1:3000) and sheep-α-mouse horseradish peroxidase antibody (1:10000).
Signal was detected using SuperSignal West Femto Maximum Sensitivity Substrate and
a CCD camera with Fotodyne software.

3.2.8 Nitrocefin hydrolysis assay
The nitrocefin assay to determine outer membrane permeability was modified
from previously described procedures (38, 39). Overnight cultures were diluted 1:60 in
30 ml LB and incubated for 2 h at 37°C with shaking. Imipenem (0.25 µg ml-1) was
added to induce β-lactamase expression. Cultures were incubated for an additional 3 h
before cells were harvested by centrifugation (5000 xg, 10 min). Cell concentration was
normalized based on OD600, and cell pellets were washed and concentrated in 50 mM
sodium phosphate buffer (pH 7.2). Aliquots of cells were treated with 0 and 0.1 mM
EDTA for 5 min. Samples were centrifuged at 15000 xg for 30 min at room temperature
and β-lactamase containing supernatant was saved. β-lactamase containing
supernatant was diluted in 50 mM sodium phosphate buffer (pH 7.2) and nitrocefin
(Calbiochem) was added at a final concentration of 100 µM in a total volume of 1 ml.
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Nitrocefin hydrolysis was measured spectrophotometrically at 482 nm and β-lactamase
activity (U/L) was calculated using the extinction coefficient of 17.4 mM-1 cm-1 for
nitrocefin. The enzyme activity per OD600 of cells was calculated and averaged over five
biological replicates. Statistical analysis was performed by ANOVA, followed by Tukey
HSD post-hoc analysis using R (version 3.2.4).

3.2.9 Measurement of pyomelanin production in strains treated with EDTA and
NTBC
LB containing 0 and 0.1 mM EDTA with 0 and 50 µM NTBC for hpd::tn and
hmgA::tn, or 0 and 900 µM NTBC for DKN343, were inoculated to an OD600 0.05 with
washed overnight cultures. Cultures were grown for approximately 24 h, then cells were
pelleted by centrifugation (2 min, 16000 xg), supernatants were collected, and the cell
pellet was suspended in an equivalent volume of LB. OD600 measurements of the
pyomelanin containing supernatant and the resuspended cells were used to calculate
the ratio of pyomelanin to cells. This ratio was averaged for three colonies tested in
triplicate and percent pyomelanin produced relative to the untreated strain was
calculated.

3.2.10 Photo analysis and image manipulation
All photos were taken on a Canon PowerShot A480 digital camera. Photos were
cropped in Adobe Photoshop and image resolution was adjusted to 600 pixels/inch.
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3.3

Results
Previous studies in our laboratory have focused on the ability of NTBC to inhibit

pyomelanin production in clinical isolates of P. aeruginosa (1). During these studies we
determined that the clinical isolate DKN343 required increased concentrations of NTBC
to inhibit pyomelanin production when compared to the pyomelanogenic control
hmgA::tn (Figure 3.2). DKN343 was isolated from a sputum sample (D. Newman,
personal communication) and was reported to have wild type PA14 sequence in hmgA
(26). Pyomelanin production typically results from either point mutations or deletions of
hmgA, or an imbalance in enzyme activity within the tyrosine catabolism pathway (2, 28,
29). We therefore investigated the mechanism of pyomelanin production and resistance
to NTBC in this clinical isolate.

3.3.1 Pyomelanin production in DKN343 results from a loss of function mutation
in HmgA.
To determine the mechanism for pyomelanin production, hmgADKN343 was PCR
amplified and sequenced, revealing two mutations when compared to PA14 hmgA; in
the resulting protein the mutated residues were A306T and H330Y (Figure 3.3). These
mutations suggested to us that, contrary to previous reports, DKN343 may produce
pyomelanin due to a loss of function mutation in HmgA. Additionally, the H330Y
mutation occurred in the HmgA iron co-factor binding site, which we hypothesized would
be required for functional HmgA. We therefore assayed the role of the tyrosine
catabolism pathway in DKN343 pyomelanin production.

75

µM NTBC

0

50

100

200

300 600

900

hpd::tn

hmgA::tn

DKN343

Figure 3.2. NTBC treatment reduced pigment production in pyomelanogenic P. aeruginosa strains.
Strains were grown in LB with the indicated concentrations of NTBC. The non-pyomelanogenic control
hpd::tn showed no pigment change in response to NTBC treatment. The pyomelanin producers
hmgA::tn and DKN343 showed dose dependent reductions in pigmentation with increasing
concentrations of NTBC. hmgA::tn was the positive control for pyomelanin production. The clinical
isolate DKN343 was less responsive to NTBC than the laboratory strain hmgA::tn, as indicated by the
requirement for higher concentrations of NTBC to reduce pyomelanin production.
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PA14
DKN343

MNLDSTALAYQSGFGNEFSSEALPGALPVGQNSPQKAPYGLYAELLSGTAFTMARSEARR 60
MNLDSTALAYQSGFGNEFSSEALPGALPVGQNSPQKAPYGLYAELLSGTAFTMARSEARR 60
************************************************************

PA14
DKN343

TWLYRITPSAKHPPFRRLERQIAGAELDAPTPNRLRWDPLALPEQPTDFLDGLLRMAANA 120
TWLYRITPSAKHPPFRRLERQIAGAELDAPTPNRLRWDPLALPEQPTDFLDGLLRMAANA 120
************************************************************

PA14
DKN343

PGDKPAGVSIYQYLANRSMERCFYDADGELLLVPQLGRLRLCTELGALQVEPLEIAVIPR 180
PGDKPAGVSIYQYLANRSMERCFYDADGELLLVPQLGRLRLCTELGALQVEPLEIAVIPR 180
************************************************************

PA14
DKN343

GMKFRVELLDGEARGYIAENHGAPLRLPDLGPIGSNGLANPRDFLAPVARYEDSRQPLQL 240
GMKFRVELLDGEARGYIAENHGAPLRLPDLGPIGSNGLANPRDFLAPVARYEDSRQPLQL 240
************************************************************

PA14
DKN343

VQKYLGELWACELDHSPLDVVAWHGNNVPYKYDLRRFNTIGTVSFDHPDPSIFTVLTSPT 300
VQKYLGELWACELDHSPLDVVAWHGNNVPYKYDLRRFNTIGTVSFDHPDPSIFTVLTSPT 300
************************************************************

PA14
DKN343

SVHGLANIDFVIFPPRWMVAENTFRPPWFHRNLMNEFMGLIQGAYDAKAGGFVPGGASLH 360
SVHGLTNIDFVIFPPRWMVAENTFRPPWFYRNLMNEFMGLIQGAYDAKAGGFVPGGASLH 360
*****:***********************:******************************

PA14
DKN343

SCMSAHGPDAESCDKAIAADLKPHRIDQTMAFMFETSQVLRPSRAALETPALQNDYDACW 420
SCMSAHGPDAESCDKAIAADLKPHRIDQTMAFMFETSQVLRPSRAALETPALQNDYDACW 420
************************************************************

PA14
DKN343

ASLVSTFNPQRR
ASLVSTFNPQRR
************

432
432

Figure 3.3. Two amino acid changes were identified in the HmgA protein sequence from the clinical
isolate DKN343 compared to the HmgA sequence from P. aeruginosa PA14. The two amino acid
changes, A306T and H330Y, are highlighted in red. The H330Y change occurred in the iron cofactor
binding site of HmgA. Clustal O (1.2.1) multiple sequence alignment of the HmgA protein from PA14
and DKN343 was used to identify the amino acid changes in DKN343.
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Because pyomelanin production requires an accumulation of HGA, we created
an in-frame deletion of hpd in DKN343, as well as in the pyomelanogenic control
hmgA::tn. Deletion of hpd resulted in a loss of pyomelanin production in both hmgA::tn
and DKN343, while complementation studies restored pyomelanin production (Figure
3.4A). These data indicate that Hpd is required for pyomelanin production in DKN343.
In order to determine if pyomelanin production is due to a loss of function
mutation in HmgADKN343, wild type hmgAPAO1 was expressed from an arabinose
inducible promoter in DKN343 and the positive control hmgA::tn (Figure 3.4B). Low
levels of HmgA expression alleviated pyomelanin production in both strains, which
demonstrated that pigment production results from a defect in HmgADKN343 function. To
ascertain whether the A306T or the H330Y mutation was responsible for this loss of
function, site directed mutagenesis was used to introduce each mutation in hmgAPAO1,
and these constructs were tested for their ability to complement the hmgA::tn strain
(Figure 3.4B). Expression of HmgAA306T eliminated pigmentation, demonstrating that this
mutation is still functional. HmgAH330Y did not affect pyomelanin production, which
indicated that the H330Y mutation is responsible for loss of function in HmgADKN343.
Western blots indicated similar levels of protein expression with both point mutations,
thereby eliminating the possibility that HmgAH330Y fails to complement due to protein
instability.
Together, these data clearly indicate that pyomelanin production in DKN343
occurs in the traditional manner: HGA is produced by Hpd, but a loss of function
mutation in HmgA prevents the conversion of HGA to 4-maleylacetoacetate. The
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Figure 3.4. Pyomelanin production in DKN343 occurs through the tyrosine catabolism pathway. A)
Hpd is required for pyomelanin production in DKN343. Deletion of hpd resulted in loss of pyomelanin
production in hmgA::tn and DKN343. Complementation of hpd deletion mutants with His-Hpd restored
pyomelanin production. The level of His-Hpd expression was determined through anti-His western
blotting. B) Point mutation in HmgA causes pyomelanin production in the clinical isolate DKN343.
Expression of WT His-HmgA in trans eliminated pyomelanin production in DKN343, which indicated
that a defect in hmgA is responsible for pyomelanin production in this strain. The H330Y mutation in
HmgA did not alleviate pyomelanin production in hmgA::tn, but had no effect on protein expression,
which indicated that the H330 residue is important for HmgA function but not protein levels. The
A306T mutation in HmgA had no effect on HmgA function, as indicated by the absence of pyomelanin
production in hmgA::tn. Anti-His western blots for both WT and mutated His-HmgA showed increased
protein expression with increasing concentrations of arabinose. Strains were grown in LB containing
gentamicin with the indicated arabinose concentrations to induce His-HmgA expression. In panels A
and B, hpd::tn was the non-pyomelanogenic control, while hmgA::tn functioned as a positive control
for pyomelanin production resulting from a defect in the tyrosine catabolism pathway.
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intracellular HGA is then secreted from DKN343 by the HatABCDE ABC transporter
where it is auto-oxidized and self-polymerized into pyomelanin.

3.3.2 Resistance to NTBC is mediated through the MexAB-OprM multi-drug efflux
pump.
Studies on the NTBC-mediated inhibition of Streptomyces avermitilis 4hydroxyphenylpyruvate dioxygenase (HppD) revealed that NTBC binds irreversibly to
the ferrous metal center in the active site of the enzyme (40). In our previous studies of
pyomelanogenic P. aeruginosa, NTBC treatment inhibited pyomelanin production in a
dose dependent manner (1). Early assays on DKN343 revealed 900 µM NTBC only
partially inhibited pyomelanin production (Figure 3.2). This is a notable increase
(approximately 12 fold) in the amount of NTBC required compared to the
pyomelanogenic laboratory strain hmgA::tn, and suggested this clinical isolate
possessed pre-existing resistance to NTBC. Because NTBC has been proposed as an
anti-virulence agent, it was necessary to ascertain the mechanism of resistance. We
investigated several ways Hpd would remain unaffected by NTBC, including mutations
in Hpd, possible sequestration of NBTC by the potential Hpd homolog PA0242, the
influence of outer membrane impermeability, and the effect of the constitutively active
multi-drug efflux pump MexAB-OprM.
A common mechanism of antibiotic resistance in bacteria is through target
alterations. We therefore investigated the possibility that the high level of resistance in
DKN343 was due to the inability of NTBC to inactivate HpdDKN343. Analysis of the
hpdDKN343 sequence failed to identify any mutations relative to the PA14 hpd sequence,
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suggesting that NTBC should be able to bind and inactivate HpdDKN343. We also
examined the P. aeruginosa PAO1 genome for proteins with homology to the active site
of Hpd with the possibility that these proteins are binding and sequestering NTBC,
thereby increasing the concentration needed for inhibition of pyomelanin production.
Using a BlastP alignment, we identified the hypothetical protein PA0242, wherein the Cterminal region of the protein has homology to Hpd, including conservation surrounding
the iron co-factor binding sites where NTBC binds (Figure 3.5A). Deletion of PA0242 in
hmgA::tn and DKN343 did not increase sensitivity of these strains to NTBC (Figure
3.5B), suggesting that PA0242 does not contribute to resistance by sequestering NTBC
away from the target enzyme Hpd. These results demonstrate that mutations in Hpd
and the presence of the potential Hpd homolog PA0242 do not have an impact on
NTBC resistance in DKN343.
P. aeruginosa is known to have low outer membrane permeability, which can
contribute to antimicrobial resistance (31). We therefore investigated the effects of
increasing outer membrane permeability on NTBC sensitivity. Similar increases in outer
membrane permeability were seen in hpd::tn, hmgA::tn, and DKN343 following
treatment with 0.1 mM EDTA when compared to the untreated strain. Nitrocefin
hydrolysis by β-lactamase released from the periplasm was used as an indicator of
outer membrane permeability (Figure 3.6A). Treatment of bacterial strains with subinhibitory concentrations of NTBC (50 µM for hmgA::tn and hpd::tn and 900 µM for
DKN343) and 0.1 mM EDTA revealed that increasing outer membrane permeability did
not increase sensitivity to NTBC (Figure 3.6B). In DKN343, the percent of pyomelanin
produced in the NTBC treated strains relative to an untreated strain was very similar
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Figure 3.5. PA0242 is not involved in NTBC resistance. A) Clustal O (1.2.0) sequence alignment of P.
aeruginosa PAO1 Hpd and PA0242 amino acid sequence. Hpd has sequence similarity to the Cterminal portion of the hypothetical protein PA0242. The iron cofactor binding sites for Hpd (H168,
H246, and E325) and PA0242 (H443, H521, and E599) are highlighted in red. B) Deletion of PA0242
had no effect on NTBC sensitivity in the pyomelanin producers hmgA::tn and DKN343. hpd::tn was the
non-pyomelanogenic control, while hmgA::tn was a positive control for pyomelanin production.
Cultures were grown with the indicated concentrations of NTBC.
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with and without EDTA treatment, but in hmgA::tn, however, the percent of pyomelanin
produced in the NTBC treated strains was actually higher in the EDTA treated strain.
These results demonstrate that low outer membrane permeability in DKN343 does not
contribute to the heightened NTBC resistance.
Multi-drug efflux pumps contribute to antimicrobial resistance by extruding a
broad range of compounds from the bacterial cell (41). We therefore tested the
contribution of the constitutively active multi-drug efflux pump MexAB-OprM to NTBC
resistance by making in-frame deletions of mexA, which codes for the membrane fusion
protein of the pump. Increased sensitivity to NTBC was observed in the hmgA::tn and
DKN343 mexA mutants, as indicated by reduced levels of NTBC (50 µM for hmgA::tn
and 100 µM for DKN343) required to inhibit pyomelanin production, and restoration of
pigmentation by complementation (Figure 3.7). These results indicate that the MexABOprM multi-drug efflux pump mediates resistance to NTBC.

3.4

Discussion
This study determined the mechanism of pyomelanin production in the clinical P.

aeruginosa sputum isolate DKN343, as well as the mechanism of resistance to NTBC.
Pyomelanin was produced through the tyrosine catabolism pathway, not an alternate
mechanism as was previously suggested for DKN343 (26). A singe amino acid change
in HmgA was identified, and is expected to result in a loss of enzyme function. In
addition, we observed that DKN343 was more resistant to NTBC than the laboratory
strain hmgA::tn (Figure 3.2), and therefore investigated the mechanism of resistance.
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Figure 3.7. Resistance to NTBC is mediated through the MexAB-OprM multi-drug efflux pump.
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were grown in LB with gentamicin and 0.05% arabinose with the indicated concentrations of NTBC.
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After testing several possible mechanisms for NTBC resistance, we determined that the
multi-drug efflux pump MexAB-OprM was responsible.
The determination that a mutation in HmgA resulted in pyomelanin production is
not unexpected. Previous studies in several bacteria have also identified mutations in
hmgA as a cause for pyomelanin production. Analysis of several naturally
pyomelanogenic strains of V. cholerae revealed that they contained either a 15 or 10
base pair (bp) deletion mutation in homogentisate oxygenase, and the 15 bp deletion
was conserved in six O139 strains that were studied (42). In a pyomelanogenic strain of
A. media WS, the hmgA gene was disrupted by an insertion of a different gene in the
opposite orientation (18). Additionally, in a Burkholderia cenocepacia pyomelanogenic
CF clinical isolate, a single point mutation in hmgA resulted in an amino acid change
from a glycine to an arginine at residue 378, and this mutation was conserved in three
of four pigmented B. cepacia complex strains (27). The G378R mutation in B.
cenocepacia was located in the iron cofactor binding region of HmgA, which could affect
iron binding and subsequent enzyme function (27). The B. cenocepacia data
corresponds with our results, in which the H330Y mutation in HmgADKN343 was located
at one of the iron cofactor binding sites (Figure 3.3) and interfered with protein function,
as indicated by a failure of HmgAH330Y to alleviate pyomelanin production when
expressed in hmgA::tn (Figure 3.4B).
Hpd, the enzyme responsible for the production of HGA from 4hydroxyphenylpyruvate during tyrosine catabolism, is very important in the production of
pyomelanin because HGA is the pyomelanin precursor molecule. Transposon
mutagenesis or deletion of hpd led to an abolishment of pyomelanin production in
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several bacterial and fungal species including B. cenocepacia, L. pneumophila, P.
aeruginosa, A. media WS, and A. fumigatus (5, 12, 18, 26, 27, 43), demonstrating the
importance of Hpd in pyomelanin production. Our results showed that deletion of hpd in
DKN343 abolished pyomelanin production (Figure 3.4A), which further demonstrated
that the tyrosine catabolism pathway mediates pyomelanin production in this strain.
P. aeruginosa has high levels of intrinsic and acquired antimicrobial resistance,
which can make it difficult to treat infections. Resistance to antimicrobial agents is
mediated by several mechanisms, including low outer membrane permeability which
can prevent antimicrobials from entering the cell, several multi-drug efflux pumps that
can extrude a broad range of compounds, chromosomally encoded β-lactamase which
can inactivate β-lactam antibiotics, and biofilm formation (31). We therefore assayed
different mechanisms to elucidate the resistance to NTBC observed in DKN343
including target alteration, sequestration by Hpd homologs, outer membrane
impermeability, and multi-drug efflux pumps.
In our studies, no mutations in hpdDKN343 were identified, indicating that target
alteration was not a source of reduced NTBC activity in DKN343. The hypothetical
protein PA0242 was identified as a potential Hpd homolog (Figure 3.5A); deletion of
PA0242, however, did not increase sensitivity to NTBC in pyomelanin producers (Figure
3.5B), which indicates that PA0242 is likely not sequestering NTBC. Additionally,
increasing outer membrane permeability with EDTA did not have an effect on NTBC
sensitivity in DKN343 (Figure 3.6).
We also tested the effects of the constitutively expressed multi-drug efflux pump
MexAB-OprM on NTBC resistance via deletion of mexA. MexAB-OprM contributes to
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intrinsic antimicrobial resistance in P. aeruginosa by extruding several classes of
antibiotics, as well as dyes, detergents, organic solvents, fatty acid synthesis inhibitors,
and homoserine lactone (44). This broad substrate specificity makes it possible that
NTBC could be a substrate for the pump. Resistance to NTBC was mediated by
MexAB-OprM, as indicated by the reduction in pyomelanin production in mexA mutants
following treatment with reduced levels of NTBC relative to the parent strain (Figure
3.7). Additionally, we observed that complementation of DKN343ΔmexA with His-MexA
did not restore NTBC resistance to the levels seen in the parent strain DKN343, as
indicated by reduced levels of pyomelanin production (Figure 3.7). This could be due to
the possibility that MexAB-OprM is hyperexpressed in DKN343, and these induction
conditions result in insufficient expression of His-MexA. It has been shown in several
studies that mutations in the MexR, NalC, or NalD regulators of mexAB-oprM
transcription result in hyperexpression of the operon in clinical isolates and laboratory
strains of P. aeruginosa (45-49). Hyperexpression of MexAB-OprM would lead to
increased levels of efflux pumps, contributing to the increased resistance to NTBC
observed in DKN343 compared to hmgA::tn, and also explain the partial
complementation of DKN343ΔmexA with His-MexA.
In summary, DKN343 produces pyomelanin because of a point mutation in
HmgA located at one of the residues involved in iron co-factor binding. This matches the
results seen in several other studies where mutations in HmgA are responsible for
pyomelanin production. We also determined that the multi-drug efflux pump MexABOprM is responsible for much of the NTBC resistance observed in DKN343, and it is
likely that efflux pumps would be a cause for NTBC resistance in other organisms.
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Since many bacterial and fungal pathogens produce pyomelanin, inhibition of
pyomelanin production is an attractive target for anti-virulence treatment. A recent study
in L. pneumophila identified a compound that inhibited phenylalanine hydroxylase,
which converts phenylalanine to tyrosine, and subsequently inhibited pyomelanin
production (50). This study demonstrated that targeting other enzymes in the
phenylalanine/tyrosine catabolism pathway may inhibit pyomelanin production in
bacteria. Targeting phenylalanine hydroxylase may have limited effectiveness in the
inhibition of pyomelanin production, as tyrosine can still be catabolized to the
pyomelanin precursor HGA. Because NTBC inhibits a later step in the catabolic
pathway, the use of both phenylalanine and tyrosine to synthesize pyomelanin is
inhibited. While NTBC shows promise as an anti-virulence therapy, its effectiveness
may be limited against an organism with a high level of pre-existing antibiotic resistance
such as P. aeruginosa. Future studies focused on the prevalence of this resistance in
pyomelanogenic microbes are required to determine the future applications of NTBC as
an anti-virulence agent.
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Chapter Four
Macrophage-based killing of pyomelanogenic
Pseudomonas aeruginosa
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4.1

Introduction
Pseudomonas aeruginosa is a Gram negative rod shaped bacterium that is found

in diverse ecological environments including soil, water, plants, and animals (1). It is
also an important opportunistic pathogen that causes acute and chronic infections in
individuals who are compromised. Chronic P. aeruginosa infections are common in the
lungs of cystic fibrosis (CF) patients, where the bacterium forms biofilms that are difficult
to eradicate, leading to persistence of infection (2). Burn patients are also very
frequently colonized by P. aeruginosa (3, 4), where the infection is acute. P. aeruginosa
produces a variety of virulence factors that allow it to colonize a host and cause
infection, including secreted proteins, toxins, and pigments (5). Pyomelanin is a reddishbrown pigment produced by some strains of P. aeruginosa (6).
Pyomelanin is derived from homogentisate during tyrosine catabolism and is
produced when there is a defect in this pathway, either 1) through deletion or mutation
of key genes, particularly hmgA that encodes homogentisate 1,2-dioxygenase, or 2) a
reduction in the activity of enzymes in the lower part of the pathway (7-12). Pyomelanin
has a variety of functions including resistance to oxidative and UV stress, electron
transfer and metal reduction, iron uptake by the bacterial cell, and persistence during
infection (10, 11, 13-20).
During bacterial infections, phagocytic cells such as polymorphonuclear
leukocytes (PMNs) and macrophages are recruited to the site of infection (21). These
phagocytic cells have several functions that are involved in clearing the infection.
Initially, they are involved in phagocytosis of the bacteria, where the bacteria are
engulfed into phagosomes that acidify and mature into phagolysosomes (22). Reactive
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oxygen species (ROS) are then produced to help bring about bacterial cell death in the
phagolysosome (22). ROS production and release into the surrounding tissue leads to
inflammation (23). Additionally, phagocytic cells are involved in the production and
release of cytokines, which function in the recruitment of additional inflammatory cells to
the site of infection (24). In individuals with CF increased PMN recruitment is associated
with the release of ROS and proteolytic enzymes that damage tissue and cause
prolonged inflammation in the lungs (23, 25, 26).
Because one of the functions of pyomelanin is increased resistance to oxidative
stress and studies have shown bacterial persistence during infection by pyomelanin
producers, we wanted to determine the effects of pyomelanin on macrophage-based
killing of P. aeruginosa. We hypothesized that if pyomelanin has a protective effect for
the bacteria against ROS produced by macrophages, we would see increased survival
of pyomelanin producing bacteria compared to pyomelanin non-producers during
infection of macrophages. We used the RAW 264.7 murine macrophage-like cell line for
our infection studies.

4.2

Materials and Methods

4.2.1 Bacterial growth conditions
A list of bacterial strains and plasmids is found in Table 4.1. Bacterial strains
were grown in LB broth or on LB plates supplemented with antibiotics were appropriate.
Antibiotics were used at the following concentrations: gentamicin 10 µg ml-1 (E. coli) and
50 µg ml-1 (P. aeruginosa); tetracycline 10 µg ml-1 (E. coli) and 75 µg ml-1 (P.
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Table 4.1. Strains and plasmids used in this study.
Strains
Description
P. aeruginosa PAO1
P. aeruginosa PAO1 (Iglewski
strain)
In-frame deletion of hpd in
P. aeruginosa Δhpd
PAO1, pyomelanin nonproducer
In-frame deletion of hmgA in
P. aeruginosa ΔhmgA
PAO1, pyomelanin producer
fhuA2 Δ(argF-lacZ)U169 phoA
E. coli DH5α
glnV44 Φ80 Δ(lacZ)M15 gyrA96
recA1 relA1 endA1 thi-1 hsdR17
E. coli S17-1
TpR SmR recA thi pro hsdR- M+
RP4 2-Tc::Mu-Km::Tn7 λpir
Strain for conjugating plasmids
RAW 264.7
Murine macrophage-like cell line
Plasmids
pEX18Tc
pEX19Gm
Δhpd-pEX18Tc
ΔhmgA-pEX19Gm

Source
Carrie Harwood
This study
This study
New England Biolabs
(27)
ATCC

Description
Suicide vector for making deletion
mutants, TcR
Suicide vector for making deletion
mutants, GmR
Fusion fragment for hpd deletion
cloned into pEX18Tc at the BamHI
and HindIII sites
Fusion fragment for hmgA deletion
cloned into pEX19Gm at the EcoRI
site, introduced HindIII site was lost
during cloning
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Source
Carrie Harwood
Carrie Harwood
This study
This study

aeruginosa); chloramphenicol 5 µg ml-1. Strains were grown at 37°C unless otherwise
indicated and stored at -80°C in 15% glycerol.

4.2.2 Generation of deletion mutants
In-frame deletion mutants of hpd and hmgA in P. aeruginosa PAO1 were
constructed by splicing by overlap extension (SOE) PCR with PAO1 DNA as template.
Primers are listed in Table 4.2. The in-frame fusions were sequenced to ensure no
mutations were introduced. The deletion alleles were cloned into pEX19Gm or pEX18Tc
and transformed into E. coli S17-1 for mating with P. aeruginosa. These constructs were
introduced into P. aeruginosa by conjugation, and merodiploids were selected on
chloramphenicol and tetracycline or gentamicin as appropriate. Resolution of the
merodiploids was achieved through 10% sucrose counter selection. Following screening
on tetracycline or gentamicin and sucrose, the deletions were confirmed by PCR.

4.2.3 RAW 264.7 murine macrophage-like cell line growth conditions
RAW 264.7 cells were routinely grown for assays in 25 or 75 cm2 cell culture
flasks in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal
bovine serum, penicillin (100 U ml-1), and streptomycin (100 µg ml-1) at 37°C and 10%
CO2. Cells were grown to 75 – 85% confluence before dissociation from cell culture
flasks with TrypLE Express. Aliquots of RAW 264.7 cells from passages 2-5 of the initial
stock cell culture were stored at -80°C in Recovery Cell Culture Freezing Medium and
thawed as needed. RAW 264.7 cells were discarded after passage 15.
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Table 4.2. List of primers used in this study.
Primer name
Primer Sequence (5’ – 3’ )a
GTAGCGGATCCCGATGCCTGCCACCGGAC
Δhpd-up-For
GAGGCTGGCGGCAGCGGGACCGGCCTCCTCGTTGT
Δhpd -up-Rev
TC
GAACAACGAGGAGGCCGGTCCCGCTGCCGCCAGCC
Δhpd -dn-For
TC
CGCCGAAGCTTGCCGCGGTGAAGCCGAGC
Δhpd -dn-Rev
CTGGAATTCCCTACCCGACGTCGCGCC
ΔhmgA-up-For
CATGGGGTTATCTCCGTTGGAGGTTCATCTGAGGCC
ΔhmgA -up-Rev
TCCGGGGAG
CTCCCCGGAGGCCTCAGATGAACCTCCAACGGAGAT
ΔhmgA -dn-For
AACCCCATG
CTGAAGCTTGGCTGTTGCTCAGGGTCAGG
ΔhmgA -dn-Rev
a
Restriction enzyme sites are underlined.
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4.2.4 RAW 264.7 killing of intracellular bacteria
The infection assay to determine RAW 264.7 killing of intracellular bacteria was
modified from previously described procedures (28). RAW 264.7 cells were seeded
(2x105 cells well-1) in 12-well cell culture plates and attached for 1 h. Overnight cultures
of Δhpd and ΔhmgA bacterial strains were diluted in LB to multiplicity of infection (MOI)
54.9 ± 7.0 and added to the wells containing attached RAW 264.7 cells to infect the
cells. Infections were synchronized by centrifuging at 130 xg for 5 min, followed by
incubation for 30 min at 37°C and 10% CO2. RAW 264.7 cells were washed 3 times with
Dulbecco’s phosphate buffered saline lacking CaCl2 and MgCl2 (DPBS) before fresh
DMEM containing 0 or 500 µg ml-1 gentamicin was added. Infected RAW 264.7 cells
were incubated for 2 h, washed 3 times with DPBS, and lysed with 0.1% Triton X-100.
Cell lysates were plated on LB to determine bacterial survival. Bacterial killing by RAW
264.7 cells was quantified for each bacterial strain, MOI, and gentamicin condition in
triplicate for three independent assays. The recovered bacterial CFU ml-1 was
normalized to percentage of inoculum to determine total RAW 264.7 associated bacteria
(0 µg ml-1 gentamicin) and intracellular bacteria (500 µg ml-1 gentamicin). Percentage of
intracellular bacteria was calculated relative to total cell-associated bacteria. To compile
results from three independent assays, viable bacteria or percentage of intracellular
bacteria was averaged for each strain and gentamicin condition. Statistical analysis was
performed by ANOVA, followed by Tukey HSD post-hoc analysis using R (version
3.2.4).
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4.2.5 RAW 264.7 bacterial association and killing of bacteria over time
The time course assay to determine RAW 264.7 bacterial association and killing
after a 15 or 30 minute infection time was modified from previously described
procedures (29). RAW 264.7 cells suspended in DMEM lacking antibiotics were
dispensed into microfuge tubes (1x106 cells per 900 µl). Overnight cultures of Δhpd and
ΔhmgA bacterial strains were diluted in LB to MOI 57.2 ± 4.2 (15 minute infection) or
MOI 58.3 ± 2.8 (30 minute infection) and added to the RAW 264.7 cells to obtain a total
volume of 1 ml. Infections occurred for 15 or 30 min at 37°C with rotation. After
infection, samples were incubated at 37°C with rotation and aliquots were taken every
30 min (starting with T=0 min after infection) for viable counts to determine RAW 264.7
total bacterial cell association and killing over time. At each time point, the entire sample
was centrifuged at 1500 rpm for 5 min and the pellet was resuspended in an equal
volume of fresh DMEM without antibiotics to remove bacteria that were not associated
with RAW 264.7 cells. An aliquot of each sample was mixed with water to lyse RAW
264.7 cells, followed by serial dilution in water. Diluted samples were spotted in triplicate
on LB to quantify the number of viable bacteria associated with RAW 264.7 cells. The
recovered bacterial CFU ml-1 for each assay was calculated as a percentage of the
inoculum. The percent bacterial survival over time was calculated by dividing the
number of viable bacteria at any given time point by the viable bacteria at the beginning
of the incubation (T=0 min). Total bacterial association with RAW 264.7 cells at 0 min
was used to determine the effect of infection time on bacterial association with RAW
264.7 cells. Three independent assays were tested for 15 and 30 minute infection times.
To compile results from three independent assays, viable bacteria or percent survival
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was averaged for each strain at each time point. Statistical analysis was performed by
ANOVA, followed by Tukey HSD post-hoc analysis using R (version 3.2.4).

4.3

Results

4.3.1 RAW 264.7 cell killing of intracellular bacteria is similar for pyomelanin
producers and non-producers.
The P. aeruginosa pyomelanin producer ΔhmgA and the non-producer Δhpd
were tested for survival in the RAW 264.7 murine macrophage-like cell line. A 30 minute
infection was followed by incubation with and without gentamicin for 2 hours (Figure
4.1). The CFU ml-1 of viable bacteria was normalized as a percentage of the bacterial
inoculum. The viable bacteria for ΔhmgA isolated from RAW 264.7 cells was
approximately two fold higher than the viable bacteria for Δhpd isolated for both total
cell-associated bacteria (those exposed to no gentamicin) and for intracellular bacteria
(those exposed to gentamicin). The difference between total cell-associated bacteria
and between intracellular bacteria when comparing both strains was not statistically
significant (Figure 4.1). These results indicated that ΔhmgA may associate slightly
better with the RAW 264.7 cells than Δhpd, which could be due to the pyomelanin
produced by this strain, as ΔhmgA and Δhpd are isogenic to each other. Within a strain,
there was a fairly large difference between total cell-associated bacteria and
intracellular bacteria when viable bacteria were examined (Figure 4.1); this difference,
however, was not statistically significant for either strain.
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Figure 4.1. RAW 264.7 killing of intracellular bacteria is similar for pyomelanin producers and nonproducers. Viable bacteria as percent of inoculum was calculated for total cell-associated (no
gentamicin treatment) and intracellular (gentamicin treated) bacteria. ΔhmgA had a higher percentage
of viable bacteria relative to inoculum than Δhpd, which indicated that more of the pyomelanin
producing ΔhmgA bacteria associated with the RAW 264.7 cells. The bacterial MOI was 54.9 ± 7.0.
Three independent assays were tested. Blue bars, Δhpd; red bars, ΔhmgA. ANOVA followed by Tukey
HSD post-hoc analysis showed no significant differences between the strains and gentamicin
treatment.
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When the percent of intracellular bacteria was calculated relative to the total cellassociated bacteria, there was a very slight difference between ΔhmgA (35.4% ± 5.8%)
and Δhpd (37.5% ± 7.1%) in RAW 264.7 cells; this difference was not statistically
significant. Additionally, the difference between total cell-associated bacteria and
percent of intracellular bacteria was significant for both strains (p<0.001). These results
indicated that the pyomelanin produced by ΔhmgA did not provide protection from RAW
264.7 killing of the intracellular bacteria under these assay conditions.

4.3.2 Association of bacterial pyomelanin producers and non-producers with
RAW 264.7 cells is similar after infection for 15 or 30 minutes.
RAW 264.7 cells exposed to ΔhmgA and Δhpd for 15 or 30 minute infections
showed slight differences in bacterial association with the cells (Figure 4.2). The viable
bacterial CFU ml-1 that was isolated for each strain was normalized to percentage of
bacterial inoculum. The results showed that there were slightly higher percentages of
RAW 264.7-associated bacteria for both ΔhmgA and Δhpd after the 30 minute infection
compared to the 15 minute infection (Figure 4.2); however, this slight increase in
bacterial association was not statistically significant for either bacterial strain. The
slightly higher association of bacteria with RAW 264.7 cells in the 30 minute infection is
likely due to the increased time. There was little difference, however, between ΔhmgA
and Δhpd association with RAW 264.7 cells within either infection time, and what little
difference was present was not statistically significant (Figure 4.2). Overall, these
results indicated that pyomelanin did not appear to play a role in bacterial association
with the RAW 264.7 cells under the conditions tested.
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Figure 4.2. Association of bacterial pyomelanin producers and non-producers with RAW 264.7 cells is
similar after infection for 15 or 30 minutes. Viable bacteria as percentage of inoculum was calculated
for each strain and condition. A 30 minute infection showed slightly higher percentages of RAW 264.7associated bacteria than a 15 minute infection. The bacterial MOI for the 15 minute infection was 57.2
± 4.2. The bacterial MOI for the 30 minute infection was 58.3 ± 2.8. Three independent assays were
tested for each infection time. Blue bars, Δhpd; red bars, ΔhmgA. ANOVA followed by Tukey HSD
post-hoc analysis showed no significant differences between the strains and infection times.
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4.3.3 Bacterial killing by RAW 264.7 cells over time is similar for pyomelanin
producers and non-producers.
The time course assay for RAW 264.7 bacterial killing was determined following
a 15 or 30 minute infection with ΔhmgA and Δhpd (Figure 4.3). The CFU ml-1 for viable
bacteria was normalized to percentage of bacterial inoculum. Most of the bacterial killing
by RAW 264.7 occurred in the first 30 to 60 minutes after infection. After both the 15
and 30 minute infections, the ΔhmgA strain generally had a slightly higher percentage of
viable bacteria associated with RAW 264.7 cells than the Δhpd strain (Figures 4.3A and
4.3C); this difference was not statistically significant. These results could be indicative of
a slightly higher association of ΔhmgA with RAW 264.7 cells during infection, which
could be due to the presence of pyomelanin. This observation also corresponds with the
data from figure 4.1 in which ΔhmgA had an approximately two fold higher percentage
of viable bacteria associated with RAW 264.7 cells compared to Δhpd.
The bacterial percent survival over time was slightly higher for ΔhmgA compared
to Δhpd after both the 15 and 30 minute infection times, but the differences between the
two strains was not statistically significant (Figures 4.3B and 4.3D). These results
indicated that the presence of pyomelanin in the ΔhmgA strain conferred very little
survival advantage, if any, during killing by RAW 264.7 cells under the tested conditions.
Additionally, increasing or decreasing the infection time had little effect on bacterial
survival during the RAW 264.7 killing assay since there were few differences between
the bacterial survival curves after different infection times.
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Figure 4.3. Time course of bacterial killing by RAW 264.7 cells following a 15 (A and B) or 30 (C and
D) minute infection is similar for pyomelanin producers and non-producers, regardless of infection
period duration. A) The ΔhmgA strain showed a higher percentage of viable bacteria relative to the
inoculum concentration than the Δhpd strain after the 15 minute infection. B) The percent survival of
bacteria isolated from RAW 264.7 cells was slightly higher for ΔhmgA than for Δhpd after the 15
minute infection. Percent survival was calculated from the number of viable bacteria at each time point
relative to 0 minutes. C) The ΔhmgA strain showed a slightly higher percentage of viable bacteria
relative to the inoculum concentration than the Δhpd strain at every time point except 0 minutes after
the 30 minute infection. D) The percent survival of bacteria isolated from RAW 264.7 cells was slightly
higher for ΔhmgA than for Δhpd after the 30 minute infection. Percent survival was calculated from the
number of viable bacteria at each time point relative to 0 minutes. Blue diamonds, Δhpd; red squares,
ΔhmgA. The bacterial MOI for the 15 minute infection was 57.2 ± 4.2. The bacterial MOI for the 30
minute infection was 58.3 ± 2.8. Three independent assays were tested for each infection time.
ANOVA followed by Tukey HSD post-hoc analysis showed no significant difference between strains.
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4.4

Discussion
It has previously been reported that pyomelanogenic P. aeruginosa showed

increased persistence in mouse models of infection compared to non-pyomelanogenic
strains (11, 20). Melanin also scavenged superoxide anion produced by macrophages
(30). Additionally, pyomelanin producing Burkholderia cenocepacia showed reduced
trafficking to RAW 264.7 lysosomes compared to a non-pigmented strain (14). These
studies all suggested that pyomelanin plays a role in bacterial persistence during
infection of phagocytes. We therefore decided to investigate the role of pyomelanin
produced by P. aeruginosa in bacterial killing by the murine macrophage-like cell line
RAW 264.7.
Our results for RAW 264.7 killing of P. aeruginosa showed that pyomelanin did
not provide a survival advantage for the bacteria upon infection of RAW 264.7 cells.
Despite testing bacterial survival under several experimental conditions, we found that
there was very little, if any, survival advantage from producing pyomelanin by the
bacteria. In the RAW 264.7 killing assay, the percentage of surviving intracellular
bacteria after a 30 minute infection and subsequent 2 hour treatment with gentamicin
was similar for both pyomelanin producers and non-producers (Figure 4.1). Percent
survival was also similar for the pyomelanin producer ΔhmgA and the non-producer
Δhpd in the time course killing assay (Figure 4.3B and 4.3D). These results correlate
with experiments done in Legionella pneumophila which found that pyomelanin
production had no role in intracellular survival of the bacterium in the host organism
Hartmannella vermiformis (31).

109

Interestingly, the total percentage of cell-associated ΔhmgA was generally higher
than that for Δhpd when they were normalized to the amount of inoculum, but the
difference between the strains was not statistically significant (Figures 4.1 and 4.3). This
result indicated that pyomelanin producers may associate better with RAW 264.7 cells
than pyomelanin non-producers. A potential explanation for this observation is that the
pyomelanin producers may be slightly more resistant to phagocytosis than nonproducers, which could allow the pyomelanogenic bacteria to associate with the RAW
264.7 cells, but not be phagocytized, resulting in higher numbers of cell-associated
bacteria. In the fungal species Penicillium marneffei and Paracoccidioides brasiliensis,
melanized cells exhibited reduced phagocytosis by macrophages (32, 33). It should be
noted, however, that these organisms produce L-DOPA melanin, and the differences
between pyomelanin and L-DOPA melanin may be important when considering these
results.
Additionally, we found that there was little difference in bacterial cell association
with the RAW 264.7 cells between the ΔhmgA and Δhpd strains after a 15 or 30 minute
infection (Figure 4.2). Although bacterial cell association was slightly higher after the 30
minute infection compared to the 15 minute infection, the difference was not statistically
significant. This difference was likely due to having increased time with which to
associate with RAW 264.7 cells in the 30 minute infection. Within an infection time,
there was no significant difference between ΔhmgA and Δhpd association with RAW
264.7 cells.
One of the differences between our studies and previously published studies is
the bacterial strains that were used. In the mouse models of infection, P. aeruginosa
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PA14 was used (11, 20), while we used P. aeruginosa PAO1, which is less virulent than
PA14 (34). The difference in virulence between PA14 and PAO1 could contribute to the
lack of protection by pyomelanin that was seen in our studies of RAW 264.7 killing of
bacteria.
Another factor that could have affected our results is that the bacterial strains
were diluted in LB for our experiments and it is unlikely that additional pyomelanin would
be produced during the duration of the assay. Therefore, the soluble pyomelanin
produced by the ΔhmgA strain was diluted, which could have resulted in decreased
protection for that strain in the RAW 264.7 killing assays. Cell surface associated
pyomelanin would have provided most of the protection for the bacteria in our assays.
In the future, different methods of examining RAW 264.7 killing of P. aeruginosa
may be investigated. First, it may be possible to quantify RAW 264.7 associated
bacterial cells, as well as bacterial uptake, via fluorescence microscopy (35). This
method may reveal differences in uptake or cell association between pyomelanin
producers and non-producers that could not be determined via viable counts. Flow
cytometry could also be used to quantify phagocytosis of pyomelanin producers and
non-producers. It is also possible to investigate bacterial survival in RAW 264.7 cells via
live/dead staining (35). This technique may give us a better understanding of how many
bacteria are taken up and killed by RAW 264.7 cells during infection and would be
independent of culturing bacteria on a plate for viable counts. Finally, we could
investigate the ability of pyomelanin produced by bacteria to scavenge ROS generated
by RAW 264.7 cells (30). This assay could reveal differences in scavenging of ROS in
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pyomelanin producers and non-producers and would contribute to our understanding of
how the RAW 264.7 cells may be killing the bacteria.
It is possible that our experimental conditions were not ideal to determine if
pyomelanin provides protection from macrophage-based killing of bacteria. For
example, a different macrophage cell line may have been more appropriate for our
experiments. Additionally, infection experiments in cell culture do not always mimic the
conditions in an animal infection, so animal based infection assays could give a different
result. The previous studies that determined that pyomelanin producers had increased
persistence during infection were performed in mouse models of infection (11, 20).
Therefore, performing our infection studies in mice may be a more appropriate
approach to studying the effects of pyomelanin on bacterial survival during infection. Of
course, even after using alternative methods to examine bacterial killing by
macrophages or using mouse models of infection, it is possible that the results could
correspond with our results and show no protective effect for pyomelanin during
infection. If that happens, it suggests that the results presented in this study are valid
and not due to experimental error or improper test conditions.
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Chapter Five
Concluding Remarks
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In this work, I have investigated mechanisms for pyomelanin production in clinical
isolates of Pseudomonas aeruginosa. Pyomelanin is an extracellular, reddish-brown
pigment derived from homogentisate (HGA), which is produced via the
phenylalanine/tyrosine catabolism pathway (1, 2). Previous studies have shown that
point mutations or chromosomal deletions in hmgA, which encodes homogentisate 1,2dioxygenase, result in the accumulation of HGA and frequently pyomelanin production
(3, 4). My work showed that the pyomelanogenic P. aeruginosa clinical isolate PA1111,
which was isolated from an acute infection in a burn patient, had a chromosomal
deletion of hmgA (Chapter 2) (5, 6). A second pyomelanogenic clinical isolate, DKN343,
which was isolated from a sputum sample, had previously been reported to have no
mutations in hmgA (7); I identified two mutations in hmgA for this strain, however, and
determined that the H330Y mutation in the iron cofactor binding site of HmgA was
responsible for pyomelanin production in this strain (Chapter 3). In addition, by deleting
hpd, which encodes the 4-hydroxyphenylpyruvate dioxygenase that produces HGA, I
determined that the phenylalanine/tyrosine catabolism pathway is required for
pyomelanin production and that inactivation of HmgA was the sole cause of pyomelanin
production in DKN343 (Chapter 3). While these results are in contrast to the previously
published study on DKN343, these results are ultimately unsurprising because several
pyomelanogenic bacterial species, including Vibrio cholerae, Aeromonas media, and
Burkholderia cenocepacia have deletions, insertions, and point mutations in hmgA,
respectively, as causes for pyomelanin production (8-10).
The Hpd inhibiting compound 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3cyclohexanedione (NTBC) has been proposed as a treatment for microbial infections by
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pyomelanin producers (11). NTBC inhibits Hpd by binding irreversibly to the ferrous
metal center in the active site of the enzyme (12). Because NTBC binds to Hpd, which
is responsible for producing the pyomelanin precursor molecule HGA, pyomelanin
production should be inhibited. I have investigated the effects of NTBC on pyomelanin
production in clinical isolates of P. aeruginosa, and determined that NTBC reduced
pyomelanin production in a dose dependent manner in both PA1111 and DKN343
(Chapters 2 and 3); DKN343, however, was more resistant to NTBC than PA1111.
Studies of NTBC resistance in DKN343 revealed that the constitutively active multi-drug
efflux pump MexAB-OprM was responsible for the inherent resistance to NTBC seen in
that strain (Chapter 3).
I also investigated the effects of NTBC on sensitivity to oxidative stress because
one of the functions of pyomelanin is resistance to oxidative stress (4, 13, 14).
Treatment of PA1111 with NTBC resulted in increased sensitivity to H2O2 oxidative
stress compared to the untreated strain (Chapter 2) (6). Additionally, I tested the
antibiotic sensitivity of PA1111 with and without NTBC to determine if reducing
pyomelanin production had an effect on minimum inhibitory concentrations (MICs). This
study was important because conflicting data on the effects of pyomelanin on antibiotic
MICs has been published. Various reports in different microbial species have stated that
antibiotic MICs were higher in pyomelanogenic organisms, that pyomelanin had no
effect on MICs, and that pyomelanin producers were more sensitive to antibiotics (4, 1521). My work showed that a reduction in pyomelanin production with NTBC had no
effect on aminoglycoside MICs (Chapter 2) (6). This demonstrated that NTBC could
possibly be used in conjunction with antibiotics.
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Finally, I investigated macrophage-based killing of pyomelanogenic and nonpyomelanogenic strains of P. aeruginosa. Pyomelanin was found to be involved in
persistence of P. aeruginosa in mouse models of infection (4, 22). Melanin also
scavenged superoxide anion produced by macrophages (23). In B. cenocepacia,
pyomelanogenic strains showed reduced trafficking to lysosomes than non-pigmented
strains (14). In my studies of macrophage-based killing of P. aeruginosa, I used the
RAW 264.7 murine macrophage-like cell line. My results showed that the
pyomelanogenic strain (ΔhmgA) showed little difference in bacterial survival during
RAW 264.7 infection compared to the non-pyomelanogenic strain (Δhpd) under different
test conditions (Chapter 4). A variety of factors could have impacted my results,
including the use of P. aeruginosa PAO1 instead of the more virulent strain PA14 that
was used in the mouse studies, dilution of extracellular pyomelanin in the assay, and
the infection assay protocol itself. It is possible that different test or quantification
conditions would have been more appropriate for these studies, such as a different way
to quantify bacterial viability, a different macrophage cell line, or using a mouse model
of infection.
In summary, my work provided some data for the potential development of NTBC
as a therapeutic agent for treating pyomelanogenic microbial infections. By elucidating
mechanisms of pyomelanin production in clinical isolates of P. aeruginosa and testing
NTBC sensitivity on those strains, I was able to 1) determine if pyomelanin production
was mediated by Hpd and 2) determine if there were any inherent mechanisms of
NTBC resistance present in those strains. My studies showed that the clinical isolates
PA1111 and DKN343 were more resistant to NTBC than the pyomelanogenic laboratory
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strain hmgA::tn, and resistance to NTBC in DKN343 was mediated by the MexAB-OprM
multi-drug efflux pump. It is possible that other pyomelanogenic organisms could have
similar mechanisms for NTBC resistance. NTBC treatment, however, rendered PA1111
more sensitive to H2O2 oxidative stress than the untreated strain. Targeting pyomelanin
for anti-virulence treatment is attractive because there are many pathogenic bacteria
and fungi that produce this pigment. NTBC does show some promise as an antivirulence agent, but its effectiveness may be limited in organisms with high levels of
antimicrobial resistance such as P. aeruginosa. Therefore, future studies should focus
on the prevalence of NTBC resistance in other pyomelanogenic organisms to determine
the future applications of NTBC as an anti-virulence therapy.
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